Serial No.: 09/505,788 Date: April 10, 2002

SUPPORT FOR AMENDMENTS

In Claim 1 the description of Ring B has been amended to more clearly conform with the restriction requirement using language disclosed in the specification. Applicants have entered new Claims 25 and 26 based on the scope of Claims 8 and 18, respectively, combined with the structural formula of 2-oxo-1,5-benzodiazepinyl. No new matter will be entered upon entry of this amendment.

REMARKS

Reconsideration and re-examination is respectfully requested.

After entering these amendments, Claims 1-4, 6, 8, 10-14, 16, 18, 20, 22, 23, 25, and 26 will be pending. Claims 1, 3, 4, 6, 8, 10, 11, 13, 14, 16, 18, 20, and 23 have been rewritten. The marked-up version of these amendments is found on a separate sheet attached to this amendment and titled "Marked-Up Version of Rewritten Claims". It is respectfully requested that the amendments above be entered before reexamination of the application.

Rejection under 35 U.S.C §112, second paragraph

Examiner has rejected Claims 15, 16, 18, 20, 23 and 24 for reasons 3f) and 3aa).

3f) Examiner has rejected Claims 15, 16, 18 and 20 for insufficient antecedent basis for the limitation "3 R¹³'s" in the structural formulae of ring B. Applicant has canceled Claim 15 in light of amendments to Claim 14 and amended Claim 14 to provide antecedent basis for the limitation "3 R¹³'s" in the structural formula of ring B. Claims 16, 18 and 20 depend from Claim 14, respectively. In view of the amendment, Applicants respectfully request the rejection be withdrawn.

Serial No.: 09/505,788 Date: April 10, 2002

3aa) Examiner has rejected Claims 23 and 24 as being vague and indefinite. Applicant has amended Claim 23 to more clearly state Alzheimer's Disease. Applicant has canceled Claim 24. Therefore, in light of the amendments Applicants respectfully request the rejection be withdrawn.

Provisional Rejection of Claims under 35 USC §101.

The Examiner has provisionally rejected Claims 5, 6, 8, 10-16, 18 and 20 under 35 U.S.C. §101 as being unpatentable over copending Application No. 09/469,939. Applicants, respectfully, request withdrawal of the provisional rejection on the basis that Application No. 09/469,939 is abandoned.

Provisional Rejection of Claims under the judicially created doctrine of obviousness-type double patenting.

The Examiner has provisionally rejected Claims 1-4 and 22-24 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over copending Application No. 09/469,939. Applicants, respectfully, request withdrawal of the provisional rejection on the basis that Application No. 09/469,939 is abandoned.

Rejection as being drawn to an improper Markush group.

The rejection of Claims 1-5, 10, 12-15, 20 and 22-24 as being drawn to an improper Markush group has been obviated by the present amendments. Withdrawal of this rejection is respectfully requested.

Rejection under 35 U.S.C §112, second paragraph

Examiner has rejected Claims 5, 6, 15, and 16 for reasons a) through d).

a) Examiner has rejected Claim 5 for lack of antecedent basis in the limitation ${}^{\mathsf{R}^{11}}$ substituted to a seven membered ring" in the third structural formula of the second

Serial No.: 09/505,788 Date: April 10, 2002

row. Withdrawal of this rejection is respectfully requested on the basis that Claim 5 has been canceled.

b) Examiner has rejected Claim 6 for lack of antecedent basis in the limitation "R¹¹ substituted to a seven membered ring" in the structural formula in the claim. Applicant's traverse the rejection.

Applicants disclose that "Ring B is a 7 membered lactam ... wherein each additional lactam carbon ... is substituted with 0-2 R¹¹...." (Claim 1, p183; et seq.) In the specification, page 92, Applicants teach what an "additional lactam carbon" is and provide examples of "R¹¹ substituted to a seven membered ring". More specifically Applicants teach R¹¹ substituted to a 2-oxo-1,4-benzodiazepinyl ring in Example B6 (page 93). Therefore, Applicants submit that there is antecedent basis in Claims 1-4 for the limitation "R¹¹ substituted to a seven membered ring" in the structural formula in Claim 6.

In view of the amendment, Applicant respectfully requests the rejection be withdrawn.

- c) Examiner has rejected Claim 15 for lack of antecedent basis in the limitation "R¹¹ substituted to a seven membered ring" in the third structural formula of the second row. Applicant's traverse the rejection. Withdrawal of this rejection is respectfully requested on the basis that Claim 5 has been canceled.
- d) Examiner has rejected Claim 16 for lack of antecedent basis in the limitation "R¹¹ substituted to a seven membered ring" in the structural formula in the claim. Applicant's traverse the rejection.

For the reason stated in b) above Applicants submit that there is antecedent basis in Claims 11-14 for the

Serial No.: 09/505,788 Date: April 10, 2002

limitation ${}^{\circ}R^{11}$ substituted to a seven membered ring" in the structural formula in Claim 16.

In view of the amendment, Applicant respectfully requests the rejection be withdrawn.

CONCLUSION

The claims of the present invention have been amended to place the Application in form for Allowance. In view of the foregoing, Applicants submit that the application is now in condition for allowance. Reconsideration and allowance is respectfully requested. Notification of such action is earnestly solicited.

Respectfully submitted,

Scott K. Larsen, Ph.D. J.D. Attorney for Applicants Registration No. 38,532 Telephone 302/467-5261

Bristol-Myers Squibb Company P.O. Box 4000, Patent Dept. Princeton, N.J. 08543-4000

Serial No.: 09/505,788 Date: April 10, 2002

Marked-Up Version of Rewritten Claims 1, 3, 4, 6, 8, 10, 11, 13, 14, 16, 18, 20, and 23.

Docket No. PH-7076-A Serial No.: 09/505,788

The subject matter to be added is in **bold** and underlined and the subject matter to be deleted is in **bold** and has been bracketed [] with square brackets.

1. (Twice Amended) A compound of Formula (I):

$$Q = \begin{pmatrix} Q & R^5 & R^{5a} & R^6 & A \\ R^3 & R^{3a} & Q & B \end{pmatrix} X^Z$$

or a pharmaceutically acceptable salt thereof, wherein:

A is O or S;

O is $-NR^1R^2$;

 R^1 is selected from: <u>H and C_1-C_6 alkyl</u>;

[H;

 C_1-C_6 alkyl substituted with 0-3 R^{1a} ;

C₃-C₁₀ carbocycle substituted with 0-3 R^{1b};

 C_6-C_{10} aryl substituted with 0-3 R^{1b} ; and

- 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{1b};
- R^{1a} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$, CF_3 ; C_3 - C_{10} carbocycle substituted with 0-3 R^{1b} ; C_6 - C_{10} aryl substituted with 0-3 R^{1b} ; and

Serial No.: 09/505,788 Date: April 10, 2002

- 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{1b};
- R^{1b} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , C_1 - C_6 alkyl, C_1 - C_4 alkoxy, C_1 - C_6 haloalkyl, and C_1 - C_4 haloalkoxy;
- R² is independently selected from H [,] <u>and</u> C₁-C₆ alkyl[, C₃-C₁₀ carbocycle, C₆-C₁₀ aryl, and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur];

```
\begin{split} R^3 & \text{ is } - (\text{CR}^7 \text{R}^{7a})_n - \text{R}^4, \\ & - (\text{CR}^7 \text{R}^{7a})_n - \text{S} - (\text{CR}^7 \text{R}^{7a})_m - \text{R}^4, \\ & - (\text{CR}^7 \text{R}^{7a})_n - \text{O} - (\text{CR}^7 \text{R}^{7a})_m - \text{R}^4, \\ & - (\text{CR}^7 \text{R}^{7a})_n - \text{N} (\text{R}^{7b}) - (\text{CR}^7 \text{R}^{7a})_m - \text{R}^4, \\ & - (\text{CR}^7 \text{R}^{7a})_n - \text{S} (= \text{O}) - (\text{CR}^7 \text{R}^{7a})_m - \text{R}^4, \\ & - (\text{CR}^7 \text{R}^{7a})_n - \text{S} (= \text{O})_2 - (\text{CR}^7 \text{R}^{7a})_m - \text{R}^4, \\ & - (\text{CR}^7 \text{R}^{7a})_n - \text{C} (= \text{O}) - (\text{CR}^7 \text{R}^{7a})_m - \text{R}^4, \\ & - (\text{CR}^7 \text{R}^{7a})_n - \text{N} (\text{R}^{7b}) \, \text{C} (= \text{O}) - (\text{CR}^7 \text{R}^{7a})_m - \text{R}^4, \\ & - (\text{CR}^7 \text{R}^{7a})_n - \text{N} (\text{R}^{7b}) \, \text{S} (= \text{O})_2 - (\text{CR}^7 \text{R}^{7a})_m - \text{R}^4, \\ & - (\text{CR}^7 \text{R}^{7a})_n - \text{N} (\text{R}^{7b}) \, \text{S} (= \text{O})_2 - (\text{CR}^7 \text{R}^{7a})_m - \text{R}^4, \\ & - (\text{CR}^7 \text{R}^{7a})_n - \text{S} (= \text{O})_2 \text{N} (\text{R}^{7b}) - (\text{CR}^7 \text{R}^{7a})_m - \text{R}^4, \\ \end{split}
```

n is 0, 1, 2, or 3;

m is 0, 1, 2, or 3;

 R^{3a} is H, OH, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_2 - C_4 alkenyl or C_2 - C_4 alkenyloxy;

 R^4 is H, OH, OR^{14a} , C_1-C_6 alkyl substituted with 0-3 R^{4a} , C_2-C_6 alkenyl substituted with 0-3 R^{4a} , C_2-C_6 alkynyl substituted with 0-3 R^{4a} ,

Serial No.: 09/505,788 Date: April 10, 2002

 C_3-C_{10} carbocycle substituted with 0-3 R^{4b} , C_6-C_{10} aryl substituted with 0-3 R^{4b} , or

- 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{4b};
- R^{4a} , at each occurrence, is independently selected from [is] H, F, Cl, Br, I, CF_3 ,

C₃-C₁₀ carbocycle substituted with 0-3 R^{4b},

 C_6-C_{10} aryl substituted with 0-3 R^{4b} , or

- 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{4b} ;
- R^{4b} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, and C_1-C_4 haloalkyl-S-;

 R^5 is H, OR^{14} ;

 C_1-C_6 alkyl substituted with 0-3 R^{5b} ;

 C_1 - C_6 alkoxy substituted with 0-3 R^{5b} ;

 C_2 - C_6 alkenyl substituted with 0-3 R^{5b} ;

 C_2 - C_6 alkynyl substituted with 0-3 R^{5b} ;

 C_3-C_{10} carbocycle substituted with 0-3 R^{5c} ;

 C_6-C_{10} aryl substituted with 0-3 R^{5c} ; or

- 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{5c} ;
- R^{5a} is H, OH, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_2 - C_4 alkenyl, or C_2 - C_4 alkenyloxy;

Amendment & Response – Docket No. DM-7076-A Serial No.: 09/505,788 Date: April 10, 2002

 R^{5b} , at each occurrence, is independently selected from: H, C_1 - C_6 alkyl, CF_3 , OR^{14} , Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$;

 C_3-C_{10} carbocycle substituted with 0-3 R^{5c} ;

 C_6-C_{10} aryl substituted with 0-3 R^{5c} ; or

- 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{5c} ;
- R^{5c} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=O)CH_3$, $S(=O)_2CH_3$, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, and C_1-C_4 haloalkyl- S^- ;
- R^6 is H; $C_1-C_6 \text{ alkyl substituted with } 0-3 \ R^{6a};$ $C_3-C_{10} \text{ carbocycle substituted with } 0-3 \ R^{6b}; \text{ or }$ $C_6-C_{10} \text{ aryl substituted with } 0-3 \ R^{6b};$
- R^{6a} , at each occurrence, is independently selected from H, C_1-C_6 alkyl, OR^{14} , Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$, aryl or CF_3 ;
- R^{6b} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , C_1 - C_6 alkyl, C_1 - C_4 alkoxy, C_1 - C_4 haloalkyl, and C_1 - C_4 haloalkoxy;
- R^7 , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO₂, CF₃, phenyl and C₁-C₄ alkyl;
- R^{7a} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , CF_3 , and C_1 - C_4 alkyl;
- R^{7b} is independently selected from H and C_1-C_4 alkyl;

Serial No.: 09/505,788 Date: April 10, 2002

Ring B is a 7 membered lactam or thiolactam,

- wherein the lactam is 2-oxo-azepinyl or thiolactam is 2-thioxo-azepinyl [saturated, partially saturated or unsaturated];
- wherein each additional lactam carbon or thiolactam carbon is substituted with 0-2 R¹¹; provided two R¹¹ substituents are present on adjacent atoms and are combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-4 R¹³; and,
- wherein [optionally,] the lactam or thiolactam contains a heteroatom selected from $[-0-, -S-, -S(=0)-, -S(=0)_2-,]$ -N=, -NH-, and -N(R¹⁰)-;
- [additionally, two R¹¹ substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-4 R¹³;
- additionally, two R¹¹ substituents on adjacent atoms may be combined to form a 5 to 6 membered heteroaryl fused radical, wherein said 5 to 6 membered heteroaryl fused radical comprises 1 or 2 heteroatoms selected from N, O, and S; wherein said 5 to 6 membered heteroaryl fused radical is substituted with 0-3 R¹³;
- additionally, two R^{11} substituents on the same or adjacent carbon atoms may be combined to form a C_3 - C_6 carbocycle substituted with 0-3 R^{13} ;
- R^{10} is H, $C(=0)R^{17}$, $C(=0)OR^{17}$, $C(=0)NR^{18}R^{19}$, $S(=0)_2NR^{18}R^{19}$, $S(=0)_2R^{17}$; C_1-C_6 alkyl optionally substituted with 0-3 R^{10a} ; C_6-C_{10} aryl substituted with 0-4 R^{10b} ; C_3-C_{10} carbocycle substituted with 0-3 R^{10b} ; or 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and

Serial No.: 09/505,788 Date: April 10, 2002

sulphur, wherein said 5 to 10 membered heterocycle is substituted with $0-3 \ R^{10b}$;

- R^{10a} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, OR^{14} , Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , or aryl substituted with 0-4 R^{10b} ;
- R^{10b} , at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, C_1 - C_4 alkoxy, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1 - C_6 alkyl, C_1 - C_4 alkoxy, C_1 - C_4 haloalkyl, C_1 - C_4 haloalkyl-S-;
- R¹¹, at each occurrence, is independently selected from H, C₁-C₄ alkoxy, Cl, F, Br, I, =0, CN, NO₂, NR¹⁸R¹⁹, C(=0)R¹⁷, C(=0)OR¹⁷, C(=0)NR¹⁸R¹⁹, S(=0)₂NR¹⁸R¹⁹, CF₃; C₁-C₆ alkyl optionally substituted with 0-3 R^{11a}; C₆-C₁₀ aryl substituted with 0-3 R^{11b}; C₃-C₁₀ carbocycle substituted with 0-3 R^{11b}; or 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{11b};
- R^{11a}, at each occurrence, is independently selected from H, C₁-C₆ alkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶, CF₃; phenyl substituted with 0-3 R^{11b}; C₃-C₆ cycloalkyl substituted with 0-3 R^{11b}; and 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{11b};
- R^{11b} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=O)CH_3$, $S(=O)_2CH_3$,

Serial No.: 09/505,788 Date: April 10, 2002

 C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, and C_1-C_4 haloalkyl-S-;

Z is H;

 C_1 - C_8 alkyl substituted with 1-3 R^{12} ;

 C_2-C_4 alkenyl substituted with 1-3 R^{12} ;

 C_2-C_4 alkynyl substituted with 1-3 R^{12} ;

 C_1-C_8 alkyl substituted with 0-3 R^{12a} ;

C2-C4 alkenyl substituted with 0-3 R12a;

 C_2-C_4 alkynyl substituted with 0-3 R^{12a} ;

 C_6-C_{10} aryl substituted with 0-4 R^{12b} ;

 C_3-C_{10} carbocycle substituted with 0-4 R^{12b} ; or

- 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{12b} ;
- R¹², at each occurrence, is independently selected from C₆-C₁₀ aryl substituted with 0-4 R^{12b};
 C₃-C₁₀ carbocycle substituted with 0-4 R^{12b}; or
 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{12b};
- R^{12a} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, -C(=0)NR¹⁵R¹⁶, CF₃, acetyl, SCH₃, S(=0)CH₃, S(=0)₂CH₃, C₁-C₆ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, or C₁-C₄ haloalkyl-S-;
- R^{12b} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, and C_1-C_4 haloalkyl-S-;

Amendment & Response - Docket No. DM-7076-A Serial No.: 09/505,788

Date: April 10, 2002

- R^{13} , at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, C_1 - C_4 alkoxy, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, and CF_3 ;
- R^{14} is H, phenyl, benzyl, C_1 - C_6 alkyl, C_2 - C_6 alkoxyalkyl, or C_3 - C_6 cycloalkyl;
- R^{14a} is H, phenyl, benzyl, or C_1 - C_4 alkyl;
- R^{15} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, benzyl, phenethyl, $(C_1-C_6$ alkyl)-C(=0)-, and $(C_1-C_6$ alkyl)- $S(=0)_2$ -;
- R^{16} , at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, benzyl, phenethyl, $(C_1$ - C_6 alkyl)-C(=0)-, and $(C_1$ - C_6 alkyl)-S(=0)₂-;
- R^{17} is H, C_1 - C_6 alkyl, C_2 - C_6 alkoxyalkyl, aryl substituted by 0-4 R^{17a} , or -CH₂-aryl substituted by 0-4 R^{17a} ;
- R^{17a} is H, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, -OH, F, Cl, Br, I, CF₃, OCF₃, SCH₃, S(O)CH₃, SO₂CH₃, -NH₂, -N(CH₃)₂, or C₁-C₄ haloalkyl;
- R^{18} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, phenyl, benzyl, phenethyl, $(C_1$ - C_6 alkyl)-C(=0)-, and $(C_1$ - C_6 alkyl)-S(=0)₂-; and
- R¹⁹, at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, phenyl, benzyl, phenethyl, $(C_1-C_6$ alkyl)-C(=0)-, and $(C_1-C_6$ alkyl)- $S(=0)_2$ -;

provided, when R13 is H,

then Z is H:

 C_4-C_8 alkyl substituted with 1-3 R^{12} ; C_2-C_4 alkenyl substituted with 1-3 R^{12} ;

Serial No.: 09/505,788 Date: April 10, 2002

 C_2-C_4 alkynyl substituted with 1-3 R^{12} ;

C₁-C₈ alkyl substituted with 0-3 R^{12a};

 C_2-C_4 alkenyl substituted with 0-3 R^{12a} ; or

 C_2-C_4 alkynyl substituted with 0-3 R^{12a} ; and

provided, when ring B is a 1,3,4,5-tetrahydro-1-(Z)-5-(R^{10})-6,6,7,7-tetra(R^{11})-2,4-dioxo-2H-1,5-diazepin-3-yl core, and R^{13} is H; then

 R^{10} is H, $C(=0)R^{17}$, $C(=0)OR^{17}$, $C(=0)NR^{18}R^{19}$, $S(=0)_2NR^{18}R^{19}$, $S(=0)_2R^{17}$; or C_1-C_6 alkyl optionally substituted with 0-3 R^{10a} ;

 $\rm R^{10a},$ at each occurrence, is independently selected from H, C1-C6 alkyl, OR 14 , Cl, F, Br, I, =0, CN, NO2, NR $^{15}\rm R^{16}$, and CF3.

2.(Amended) A compound, according to Claim 1, of Formula
 (Ia):

or a pharmaceutically acceptable salt thereof, wherein:

Z is H;

 C_1-C_8 alkyl substituted with 0-3 R^{12a} ; C_2-C_4 alkenyl substituted with 0-3 R^{12a} ; or C_2-C_4 alkynyl substituted with 0-3 R^{12a} .

(Amended) A compound according to Claim 2 of Formula(Ia)

Serial No.: 09/505,788 Date: April 10, 2002

(Ia)

or a pharmaceutically acceptable salt thereof,

wherein:

 R^3 is $-(CR^7R^{7a})_n-R^4$, $-(CR^7R^{7a})_n-S-(CR^7R^{7a})_m-R^4$, $-(CR^7R^{7a})_n-O-(CR^7R^{7a})_m-R^4$, or

 $-(CR^{7}R^{7a})_{n}-N(R^{7b})-(CR^{7}R^{7a})_{m}-R^{4};$

n is 0, 1, or 2;

m is 0, 1, or 2;

R^{3a} is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, allyl, or 3-buten-1-yl;

 R^4 is H, OH, OR^{14a} ,

 C_1-C_6 alkyl substituted with 0-3 R^{4a} ,

 C_2-C_6 alkenyl substituted with 0-3 R^{4a} ,

 C_2 - C_6 alkynyl substituted with 0-3 R^{4a} ,

 C_3-C_{10} carbocycle substituted with 0-3 R^{4b} ,

 C_6-C_{10} aryl substituted with 0-3 R^{4b} , or

- 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{4b};
- R^{4a} , at each occurrence, is independently selected from [is] H, F, Cl, Br, I, CF₃,

 C_3-C_{10} carbocycle substituted with 0-3 R^{4b} ,

 C_6-C_{10} aryl substituted with 0-3 R^{4b} , or

5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and

Serial No.: 09/505,788 Date: April 10, 2002

sulphur, wherein said 5 to 10 membered heterocycle is substituted with $0-3\ R^{4b}$;

 R^{4b} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, CF₃, acetyl, SCH₃, S(=0)CH₃, S(=0)₂CH₃, C₁-C₆ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, and C₁-C₄ haloalkoxy;

 R^5 is H, OR^{14} ;

 C_1-C_6 alkyl substituted with 0-3 R^{5b} ;

 C_1-C_6 alkoxy substituted with 0-3 R^{5b} ;

C2-C6 alkenyl substituted with 0-3 R5b;

 C_2 - C_6 alkynyl substituted with 0-3 R^{5b} ;

 C_3-C_{10} carbocycle substituted with 0-3 R^{5c} ;

 C_6-C_{10} aryl substituted with 0-3 R^{5c} ; or

5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{5c};

 R^{5a} is H or C_1 - C_4 alkyl;

 $\rm R^{5b},$ at each occurrence, is independently selected from: H, C1-C6 alkyl, CF3, OR^{14}, Cl, F, Br, I, =0, CN, NO_2, NR^{15}R^{16};

 C_3-C_{10} carbocycle substituted with 0-3 R^{5c} ;

 C_6-C_{10} aryl substituted with 0-3 R^{5c} ; or

- 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{5c};
- R^{5c} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, and C_1-C_4 haloalkoxy;

Serial No.: 09/505,788 Date: April 10, 2002

R⁶ is H, methyl, or ethyl;

 R^7 , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO₂, CF₃, phenyl and C₁-C₄ alkyl;

 R^{7a} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO₂, CF₃, and C₁-C₄ alkyl;

R^{7b} is independently selected from H, methyl, ethyl, propyl, and butyl;

Ring B is selected from

[a 7 membered lactam or thiolactam,

wherein the lactam or thiolactam is saturated, partially saturated or unsaturated;

wherein each additional lactam carbon or thiolactam carbon is substituted with 0-2 R^{11} ; and,

- optionally, the lactam or thiolactam contains a heteroatom selected from, -0-, -S-, -S(=0)-, $-S(=0)_2-$, -N=, -NH-, and $-N(R^{10})-$;
- additionally, two R¹¹ substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-3 R¹³;
- additionally, two R¹¹ substituents on adjacent atoms may be combined to form a 5 to 6 membered heteroaryl fused radical, wherein said 5 to 6 membered heteroaryl fused radical comprises 1 or 2 heteroatoms selected from N, O,

Serial No.: 09/505,788 Date: April 10, 2002

and S; wherein said 5 to 6 membered heteroaryl fused radical is substituted with 0-3 R¹³;

additionally, two R^{11} substituents on the same or adjacent carbon atoms may be combined to form a C_3 - C_6 carbocycle substituted with 0-3 R^{13} ;

- R^{10} is H, $C(=0)R^{17}$, $C(=0)OR^{17}$, $C(=0)NR^{18}R^{19}$, $S(=0)_2NR^{18}R^{19}$, $S(=0)_2R^{17}$; C_1 - C_6 alkyl optionally substituted with 0-2 R^{10a} ; C_6 - C_{10} aryl substituted with 0-4 R^{10b} ; C_3 - C_{10} carbocycle substituted with 0-3 R^{10b} ; or 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{10b} ;
- R^{10a} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, OR^{14} , Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-4 R^{10b} ;
- R^{10b} , at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, C_1 - C_4 alkoxy, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, or CF_3 ;
- R¹¹, at each occurrence, is independently selected from H, C₁-C₄ alkoxy, Cl, F, Br, I, [=0,] CN, NO₂, NR¹⁸R¹⁹, C(=0)R¹⁷, C(=0)OR¹⁷, C(=0)NR¹⁸R¹⁹, S(=0)₂NR¹⁸R¹⁹, CF₃; C₁-C₆ alkyl optionally substituted with 0-3 R^{11a}; C₆-C₁₀ aryl substituted with 0-3 R^{11b}; C₃-C₁₀ carbocycle substituted with 0-3 R^{11b}; or 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{11b};

Serial No.: 09/505,788 Date: April 10, 2002

- R^{11a} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, OR^{14} , Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-3 R^{11b} ;
- R^{11b}, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, CF₃, acetyl, SCH₃, S(=0)CH₃, S(=0)₂CH₃, C₁-C₆ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, and C₁-C₄ haloalkoxy;
- Z is H; $C_1-C_6 \text{ alkyl substituted with } 0-3 \text{ R}^{12a};$ $C_2-C_4 \text{ alkenyl substituted with } 0-3 \text{ R}^{12a}; \text{ or }$ $C_2-C_4 \text{ alkynyl substituted with } 0-3 \text{ R}^{12a};$
- R^{12a} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=O)CH_3$, $S(=O)_2CH_3$, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, and C_1-C_4 haloalkoxy;
- R^{13} , at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, C_1 - C_4 alkoxy, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, and CF_3 ;
- R^{14} is H, phenyl, benzyl, C_1 - C_6 alkyl, or C_2 - C_6 alkoxyalkyl;
- R^{14a} is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;
- R^{15} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, benzyl, phenethyl, $(C_1-C_6$ alkyl)-C(=0)-, and $(C_1-C_6$ alkyl)-S(=0)₂-;
- R^{16} , at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, benzyl, phenethyl, $(C_1$ - C_6 alkyl)-C(=0)-, and $(C_1$ - C_6 alkyl)- $S(=0)_2$ -;
- ${
 m R}^{17}$ is H, ${
 m C}_1{
 m -}{
 m C}_6$ alkyl, ${
 m C}_2{
 m -}{
 m C}_6$ alkoxyalkyl, aryl substituted by 0-4 ${
 m R}^{17a}$, or

Serial No.: 09/505,788 Date: April 10, 2002

-CH₂-aryl substituted by 0-4 R^{17a};

- R^{17a} is H, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, -OH, F, Cl, Br, I, CF₃, OCF₃, SCH₃, S(O)CH₃, SO₂CH₃, -NH₂, -N(CH₃)₂, or C₁-C₄ haloalkyl;
- R^{18} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, phenyl, benzyl, phenethyl, $(C_1$ - C_6 alkyl)-C(=0)-, and $(C_1$ - C_6 alkyl)-S(=0)₂-; and
- R^{19} , at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, phenyl, benzyl, phenethyl, $(C_1$ - C_6 alkyl)-C(=0)-, and $(C_1$ - C_6 alkyl)-S(=0)₂-.
- **4.** (Twice Amended) A compound according to Claim 3 of Formula (Ia)

$$\begin{array}{c|c} O & R^5 & R^{5a} & R^6 \\ \hline H_2 N & R^3 & R^{3a} & O \end{array} \qquad \begin{array}{c} A & A \\ B & N \end{array} \qquad Z$$

(Ia)

or a pharmaceutically acceptable salt thereof,

wherein:

 R^3 is $-(CHR^7)_n-R^4$,

n is 0 or 1;

R^{3a} is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, allyl, or 3-buten-1-yl;

 R^4 is H, OH, OR^{14a} ,

 C_1-C_4 alkyl substituted with 0-2 R^{4a} ,

 C_2-C_4 alkenyl substituted with 0-2 R^{4a} ,

 C_2-C_4 alkynyl substituted with 0-1 R^{4a} ,

Serial No.: 09/505,788 Date: April 10, 2002

 C_3 - C_6 carbocycle substituted with 0-3 R^{4b} , C_6 - C_{10} aryl substituted with 0-3 R^{4b} , or

- 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R4b;
- ${\tt R^{4a}},$ at each occurrence, is independently selected from [is] H, F, Cl, Br, I, CF3,

 C_3-C_6 carbocycle substituted with 0-3 R^{4b} ,

phenyl substituted with 0-3 R4b, or

- 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R4b;
- R^{4b} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_4 alkyl, C_1-C_3 alkoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;

 R^5 is H, OR^{14} ;

 C_1-C_4 alkyl substituted with 0-3 R^{5b} ;

 C_2-C_4 alkenyl substituted with 0-3 R^{5b} ;

 C_2-C_4 alkynyl substituted with 0-3 R^{5b} ;

R^{5a} is H, methyl, ethyl, propyl, or butyl;

 R^{5b} , at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, CF_3 , OR^{14} , Cl, F, Br, I, =0;

 C_3-C_6 carbocycle substituted with 0-3 R^{5c} ;

phenyl substituted with 0-3 R5c; or

5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{5c};

Serial No.: 09/505,788 Date: April 10, 2002

 R^{5c} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_4 alkyl, C_1-C_3 alkoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;

 R^6 is H;

 \mathbb{R}^7 , at each occurrence, is independently selected from H, F, \mathbb{CF}_3 , methyl, and ethyl;

Ring B is selected from

[a 7 membered lactam or thiolactam, wherein the lactam or thiolactam is saturated, partially saturated or unsaturated;

wherein each additional lactam carbon or thiolactam carbon is substituted with 0-2 R^{11} ; and, optionally, the lactam or thiolactam contains a heteroatom selected from -N=, -NH-, and -N(R^{10})-;

- additionally, two R^{11} substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-2 R^{13} ;
- additionally, two R¹¹ substituents on adjacent atoms may be combined to form a 5 to 6 membered heteroaryl fused radical, wherein said 5 to 6 membered heteroaryl fused radical comprises 1 or 2 heteroatoms selected from N, O, and S; wherein said 5 to 6 membered heteroaryl fused radical is substituted with 0-2 R¹³;

Serial No.: 09/505,788 Date: April 10, 2002

additionally, two R^{11} substituents on the same or adjacent carbon atoms may be combined to form a C_3 - C_6 carbocycle substituted with 0-2 R^{13} ;

- R¹⁰ is H, C(=0)R¹⁷, C(=0)OR¹⁷;

 C₁-C₄ alkyl optionally substituted with 0-1 R^{10a};

 phenyl substituted with 0-4 R^{10b};

 C₃-C₆ carbocycle substituted with 0-3 R^{10b}; or

 5 to 6 membered heterocycle containing 1 to 4

 heteroatoms selected from nitrogen, oxygen, and

 sulphur, wherein said 5 to 6 membered heterocycle is

 substituted with 0-3 R^{10b};
- R^{10a} [, at each occurrence,] is [independently] selected from H, C_1 - C_4 alkyl, OR^{14} , Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-4 R^{10b} ;
- $\rm R^{10b},$ at each occurrence, is independently selected from H, OH, C₁-C₄ alkyl, C₁-C₃ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;
- R^{11} [, at each occurrence,] is [independently] selected from H, C_1 - C_4 alkoxy, C_1 , C_1 , C_1 , C_1 , C_2 , C_3 ;
 - C_1-C_6 alkyl optionally substituted with 0-3 R^{11a} ; C_6-C_{10} aryl substituted with 0-3 R^{11b} ;
 - $C_3-\underline{C_6}$ [6] carbocycle substituted with 0-3 R^{11b} ; or
 - 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{11b};
- R^{11a} , at each occurrence, is independently selected from H, C_1-C_4 alkyl, OR^{14} , F, =0, $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-3 R^{11b} ;

Serial No.: 09/505,788 Date: April 10, 2002

- R^{11b} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , C_1-C_4 alkyl, C_1-C_3 alkoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- Z is H; $C_1-C_4 \text{ alkyl substituted with } 0-3 \text{ R}^{12a};$ $C_2-C_4 \text{ alkenyl substituted with } 0-3 \text{ R}^{12a}; \text{ or }$ $C_2-C_4 \text{ alkynyl substituted with } 0-3 \text{ R}^{12a};$
- R^{12a} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_4 alkyl, C_1-C_3 alkoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- $\rm R^{13},$ at each occurrence, is independently selected from H, OH, C1-C6 alkyl, C1-C4 alkoxy, Cl, F, Br, I, CN, NO2, NR^{15}R^{16}, and CF3;
- R^{14} is H, phenyl, benzyl, C_1-C_4 alkyl, or C_2-C_4 alkoxyalkyl;
- R^{15} , at each occurrence, is independently selected from H, C_1 - C_4 alkyl, benzyl, phenethyl, $(C_1-C_4$ alkyl)-C(=0)-, and $(C_1-C_4$ alkyl)- $S(=0)_2$ -;
- R^{16} , at each occurrence, is independently selected from H, OH, C_1 - C_4 alkyl, benzyl, phenethyl, $(C_1$ - C_4 alkyl)-C(=0)-, and $(C_1$ - C_4 alkyl)-S(=0)₂-;
- R¹⁷ is H, methyl, ethyl, propyl, butyl, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, phenyl substituted by 0-3 R^{17a}, or -CH₂-phenyl substituted by 0-3 R^{17a};
- R^{17a} is H, methyl, methoxy, -OH, F, Cl, CF₃, or OCF₃;
- ${\bf R}^{18}$, at each occurrence, is independently selected from

Serial No.: 09/505,788 Date: April 10, 2002

H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and

 R^{19} , at each occurrence, is independently selected from H, methyl, and ethyl.

6. (Twice Amended) A compound according to Claim <u>4</u> [5] of Formula (Ic):

$$H_2N$$
 R^5
 H
 N
 Z
 R^{13}
 R^{13}

(Ic)

or a pharmaceutically acceptable salt thereof wherein

 R^3 is R^4 ,

 R^4 is C_1-C_4 alkyl substituted with 0-1 R^{4a} , C_2-C_4 alkenyl substituted with 0-1 R^{4a} , or C_2-C_4 alkynyl substituted with 0-1 R^{4a} ;

 R^{4a} [, at each occurrence,] is [independently] selected from H, F, CF_3 ,

 C_3-C_6 carbocycle substituted with 0-3 R^{4b} , phenyl substituted with 0-3 R^{4b} , or

5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{4b}; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

Serial No.: 09/505,788 Date: April 10, 2002

 R^{4b} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;

 R^5 is C_1 - C_4 alkyl substituted with 0-1 R^{5b} ; C_2 - C_4 alkenyl substituted with 0-1 R^{5b} ; C_2 - C_4 alkynyl substituted with 0-1 R^{5b} ;

R^{5b}[, at each occurrence,] is [independently] selected from:

H, methyl, ethyl, propyl, butyl, CF₃, OR¹⁴, =O;

C₃-C₆ carbocycle substituted with 0-2 R^{5c};

phenyl substituted with 0-3 R^{5c}; or

5 to 6 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 6 membered heterocycle is

substituted with 0-3 R^{5c}; wherein said 5 to 6 membered

heterocycle is selected from pyridinyl, pyrimidinyl,

triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl,

piperazinyl, piperidinyl, pyrazolyl, imidazolyl,

oxazolyl, isoxazolyl, and tetrazolyl;

 R^{5c} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;

R¹¹[, at each occurrence,] is [independently] selected from H, [=0,] NR¹⁸R¹⁹, CF₃;

 C_1-C_4 alkyl optionally substituted with 0-1 R^{11a} ; phenyl substituted with 0-3 R^{11b} ;

 C_3 - C_6 carbocycle substituted with 0-3 R^{11b} ; and

5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{11b}; wherein said 5 to 6

Amendment & Response – Docket No. DM-7076-A Serial No.: 09/505,788 Date: April 10, 2002

membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

- R^{11a} [, at each occurrence,] is [independently] selected from H, C_1 - C_4 alkyl, OR^{14} , F, [C1,] =0, $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-3 R^{11b} ;
- R^{11b} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1 - C_2 haloalkyl, and C_1 - C_2 haloalkoxy;
- Z is H; $C_1-C_4 \text{ alkyl substituted with } 0-3 \text{ R}^{12a};$ $C_2-C_4 \text{ alkenyl substituted with } 0-3 \text{ R}^{12a}; \text{ or }$ $C_2-C_4 \text{ alkynyl substituted with } 0-3 \text{ R}^{12a};$
- R^{12a} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R^{13} , at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, Cl, F, Br, CN, $NR^{15}R^{16}$, and CF_3 ;
- R^{14} is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;
- R^{15} , at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;
- R^{16} , at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl, methyl-C(=0)-, ethyl-C(=0)-, methyl-S(=0)₂-, and ethyl-S(=0)₂-;

Serial No.: 09/505,788 Date: April 10, 2002

- R¹⁸, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and
- R^{19} , at each occurrence, is independently selected from H, methyl, and ethyl.
- 8. (Twice Amended) A compound according to Claim <u>4</u> [5] of Formula (Ie):

$$H_2N$$
 R^5
 H_2N
 R^5
 R^5
 R^5
 R^5
 R^5
 R^5
 R^{13}
 R^{13}
 R^{13}

or a pharmaceutically acceptable salt thereof wherein:

 R^3 is R^4 ,

 R^4 is C_1 - C_4 alkyl substituted with 0-1 R^{4a} , C_2 - C_4 alkenyl substituted with 0-1 R^{4a} , or C_2 - C_4 alkynyl substituted with 0-1 R^{4a} ;

 R^{4a} [, at each occurrence,] is [independently] selected from H, F, CF_3 ,

 C_3-C_6 carbocycle substituted with 0-3 R^{4b} , phenyl substituted with 0-3 R^{4b} , or

5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{4b}; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl,

Serial No.: 09/505,788 Date: April 10, 2002

piperazinyl, piperidinyl, pyrazolyl, imidazolyl,
oxazolyl, isoxazolyl, and tetrazolyl;

- R^{4b} , at each occurrence, is independently selected from H, OH, C1, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R^5 is C_1 - C_4 alkyl substituted with 0-1 R^{5b} ; C_2 - C_4 alkenyl substituted with 0-1 R^{5b} ; C_2 - C_4 alkynyl substituted with 0-1 R^{5b} ;
- R^{5b}[, at each occurrence,] is [independently] selected from:

 H, methyl, ethyl, propyl, butyl, CF₃, OR¹⁴, =O;

 C₃-C₆ carbocycle substituted with 0-2 R^{5c};

 phenyl substituted with 0-3 R^{5c}; or

 5 to 6 membered heterocycle containing 1 to 4

 heteroatoms selected from nitrogen, oxygen, and

 sulphur, wherein said 5 to 6 membered heterocycle is

 substituted with 0-3 R^{5c}; wherein said 5 to 6 membered

 heterocycle is selected from pyridinyl, pyrimidinyl,

 triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl,

 piperazinyl, piperidinyl, pyrazolyl, imidazolyl,

 oxazolyl, isoxazolyl, and tetrazolyl;
- R^{5c} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R^{10} is H, $C(=0)R^{17}$, $C(=0)OR^{17}$; C_1-C_4 alkyl optionally substituted with 0-1 R^{10a} ; phenyl substituted with 0-4 R^{10b} ; C_3-C_6 carbocycle substituted with 0-3 R^{10b} ; or 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is

Serial No.: 09/505,788 Date: April 10, 2002

substituted with 0-3 R^{10b}; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

- R^{10a} [, at each occurrence,] is [independently] selected from H, methyl, ethyl, propyl, butyl, OR^{14} , Cl, F, =0, $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-4 R^{10b} ;
- R^{10b} , at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl, F, $NR^{15}R^{16}$, and CF_3 ;
- Z is H; $C_1-C_4 \text{ alkyl substituted with } 0-3 \text{ R}^{12a};$ $C_2-C_4 \text{ alkenyl substituted with } 0-3 \text{ R}^{12a}; \text{ or }$ $C_2-C_4 \text{ alkynyl substituted with } 0-3 \text{ R}^{12a};$
- R^{12a} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R^{13} , at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, Cl, F, Br, CN, $NR^{15}R^{16}$, and CF_3 ;
- R¹⁴ is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;
- R¹⁵, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;
- R¹⁶, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl, methyl-C(=0)-, ethyl-C(=0)-, methyl-S(=0)₂-, and ethyl-S(=0)₂-;

Amendment & Response - Docket No. DM-7076-A Serial No.: 09/505,788

Date: April 10, 2002

```
R<sup>17</sup> is H, methyl, ethyl, propyl, butyl, methoxymethyl,
      ethoxymethyl, methoxyethyl, ethoxyethyl,
     phenyl substituted by 0-3 R^{17a}, or
      -CH<sub>2</sub>-phenyl substituted by 0-3 R^{17a};
```

 R^{17a} is H, methyl, methoxy, -OH, F, Cl, CF₃, or OCF₃;

- R¹⁸, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and
- ${\bf R}^{19}$, at each occurrence, is independently selected from H, methyl, and ethyl.
- 10. (Twice Amended) A compound, according to one of Claims 6, [7,] 8, or <u>25</u> [9,] wherein:

```
R^3 is -CH_3, -CH_2CH_3, -CH_2CH_2CH_3, -CH_2CH_2CH_3,
   -CH(CH_3)_2, -CH(CH_3)CH_2CH_3, -CH_2CH(CH_3)_2,
   -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>,
   -CH=CH_2, -CH_2CH=CH_2, -CH_2C(CH_3)=CH_2,
   -CH2CH2CH=CH2,
   cis-CH<sub>2</sub>CH=CH(CH<sub>3</sub>),
   trans-CH<sub>2</sub>CH=CH(CH<sub>3</sub>),
   -C \equiv CH, -CH_2C \equiv CH, -CH_2C \equiv C(CH_3),
   cyclopropyl-CH2-, cyclobutyl-CH2-, cyclopentyl-CH2-,
   cyclohexyl-CH2-, cyclopropyl-CH2CH2-,
   cyclobutyl-CH2CH2-, cyclopentyl-CH2CH2-,
   cyclohexyl-CH<sub>2</sub>CH<sub>2</sub>-, phenyl-CH<sub>2</sub>-,
   (2-F-pheny1)CH_2-, (3-F-pheny1)CH_2-, (4-F-pheny1)CH_2-,
   (2-C1-pheny1)CH_2-, (3-C1-pheny1)CH_2-, (4-C1-pheny1)CH_2-,
   (2,3-diF-phenyl)CH<sub>2</sub>-, (2,4-diF-phenyl)CH<sub>2</sub>-,
   (2,5-diF-phenyl)CH<sub>2</sub>-, (2,6-diF-phenyl)CH<sub>2</sub>-,
   (3,4-diF-phenyl)CH_2-, (3,5-diF-phenyl)CH_2-,
   (2,3-diCl-phenyl)CH<sub>2</sub>-, (2,4-diCl-phenyl)CH<sub>2</sub>-,
```

Amendment & Response – Docket No. DM-7076-A Serial No.: 09/505,788 Date: April 10, 2002

```
(2,5-diCl-phenyl)CH_2-, (2,6-diCl-phenyl)CH_2-,
     (3,4-diCl-phenyl)CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>-,
     (3-F-4-Cl-phenyl)CH<sub>2</sub>-, (3-F-5-Cl-phenyl)CH<sub>2</sub>-,
     (3-Cl-4-F-phenyl)CH_2-, phenyl-CH_2CH_2-,
     (2-F-pheny1)CH_2CH_2-, (3-F-pheny1)CH_2CH_2-,
     (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
     (3-Cl-phenyl)CH_2CH_2-, (4-Cl-phenyl)CH_2CH_2-,
     (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
     (2,5-diF-pheny1)CH<sub>2</sub>CH<sub>2</sub>-, (2,6-diF-pheny1)CH<sub>2</sub>CH<sub>2</sub>-,
     (3,4-diF-pheny1)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diF-pheny1)CH<sub>2</sub>CH<sub>2</sub>-,
     (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
     (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
     (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
     (3-F-4-Cl-pheny1)CH<sub>2</sub>CH<sub>2</sub>-, or <math>(3-F-5-Cl-pheny1)CH<sub>2</sub>CH<sub>2</sub>-,
R^5 is -CH_3, -CH_2CH_3, -CH_2CH_2CH_3, -CH_1CH_3), -CH_2CH_2CH_3,
    -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>,
    -CH_2CH_2CH_2CH_3, -CH(CH_3)CH_2CH_3, -CH_2CH(CH_3)CH_2CH_3,
    -CH_2CH_2CH(CH_3)_2, -CH(CH_2CH_3)_2, -CH_2CF_3, -CH_2CH_2CF_3,
    -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, -CH=CH<sub>2</sub>, -CH<sub>2</sub>CH=CH<sub>2</sub>,
    -CH=CHCH<sub>3</sub>, cis-CH<sub>2</sub>CH=CH(CH<sub>3</sub>), trans-CH<sub>2</sub>CH=CH(CH<sub>3</sub>),
    trans-CH<sub>2</sub>CH=CH(C<sub>6</sub>H<sub>5</sub>), -CH<sub>2</sub>CH=C(CH<sub>3</sub>)<sub>2</sub>, cis-CH<sub>2</sub>CH=CHCH<sub>2</sub>CH<sub>3</sub>,
    trans-CH<sub>2</sub>CH=CHCH<sub>2</sub>CH<sub>3</sub>, cis-CH<sub>2</sub>CH<sub>2</sub>CH=CH(CH<sub>3</sub>),
    trans-CH_2CH_2CH=CH(CH_3), trans-CH_2CH=CHCH_2(C_6H_5),
    -C \equiv CH, -CH_2C \equiv CH, -CH_2C \equiv C(CH_3), -CH_2C \equiv C(C_6H_5),
    -CH_2CH_2C \equiv CH, -CH_2CH_2C \equiv C(CH_3), -CH_2CH_2C \equiv C(C_6H_5),
    cyclopropyl-CH2-, cyclobutyl-CH2-, cyclopentyl-CH2-,
    cyclohexyl-CH<sub>2</sub>-, (2-CH<sub>3</sub>-cyclopropyl)CH<sub>2</sub>-,
    (3-CH_3-cyclobutyl)CH_2-
    cyclopropyl-CH<sub>2</sub>CH<sub>2</sub>-, cyclobutyl-CH<sub>2</sub>CH<sub>2</sub>-,
    cyclopentyl-CH<sub>2</sub>CH<sub>2</sub>-, cyclohexyl-CH<sub>2</sub>CH<sub>2</sub>-,
    (2-CH<sub>3</sub>-cyclopropyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-CH<sub>3</sub>-cyclobutyl)CH<sub>2</sub>CH<sub>2</sub>-,
    phenyl-CH_2-, (2-F-phenyl)CH_2-, (3-F-phenyl)CH_2-,
    (4-F-phenyl)CH<sub>2</sub>-, furanyl-CH<sub>2</sub>-, thienyl-CH<sub>2</sub>-,
    pyridyl-CH<sub>2</sub>-, 1-imidazolyl-CH<sub>2</sub>-, oxazolyl-CH<sub>2</sub>-,
    isoxazolyl-CH<sub>2</sub>-,
    phenyl-CH_2CH_2-, (2-F-phenyl)CH_2CH_2-, (3-F-phenyl)CH_2CH_2-,
```

Amendment & Response - Docket No. DM-7076-A Serial No.: 09/505,788 Date: April 10, 2002

- Z is methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl, sbutyl, t-butyl, or allyl;
- R¹⁰ is H, methyl, ethyl, phenyl, benzyl, phenethyl, 4-F-phenyl, (4-F-phenyl)CH₂-, (4-F-phenyl)CH₂CH₂-, 4-Cl-phenyl, (4-Cl-phenyl)CH₂-, (4-Cl-phenyl)CH₂-, 4-CH₃-phenyl, (4-CH₃-phenyl)CH₂-, (4-CH₃-phenyl)CH₂-, 4-CF₃-phenyl, (4-CF₃-phenyl)CH₂-, or (4-CF₃-phenyl)CH₂-;
- R¹¹, at each occurrence, is independently selected from H, =0, methyl, ethyl, phenyl, benzyl, phenethyl, 4-F-phenyl, (4-F-phenyl)CH₂-, (4-F-phenyl)CH₂CH₂-, 3-F-phenyl, (3-F-phenyl)CH₂-, (3-F-phenyl)CH₂CH₂-, 2-F-phenyl, (2-F-phenyl)CH₂-, (2-F-phenyl)CH₂CH₂-, 4-Cl-phenyl, (4-Cl-phenyl)CH₂-, (4-Cl-phenyl)CH₂CH₂-, 3-Cl-phenyl, (3-Cl-phenyl)CH₂-, (3-Cl-phenyl)CH₂CH₂-, 4-CH₃-phenyl, (4-CH₃-phenyl)CH₂-, (4-CH₃-phenyl)CH₂CH₂-, 3-CH₃-phenyl, (3-CH₃-phenyl)CH₂-, (3-CH₃-phenyl)CH₂CH₂-, 4-CF₃-phenyl, (4-CF₃-phenyl)CH₂-, (4-CF₃-phenyl)CH₂CH₂-, pyrid-2-yl, pyrid-3-yl, or pyrid-4-yl, and
- R^{13} , at each occurrence, is independently selected from H, F, Cl, OH, -CH₃, -CH₂CH₃, -OCH₃, or -CF₃.
- 11. (Amended) A compound according to Claim 2 selected from:
- (2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;
- (2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-butanediamide;

Serial No.: 09/505,788 Date: April 10, 2002

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3R)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3R)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-butanediamide:

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-methyl-3-allyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-methyl-3-allyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-methyl-3-propyl-butanediamide;

(2R) N1-[1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-methyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-phenyl-7-chloro-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-7-chloro-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

```
Amendment & Response - Docket No. DM-7076-A Serial No.: 09/505,788
```

Date: April 10, 2002

(2R,3S) N1-[(3R)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-7-chloro-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(2-fluorophenyl)-7-chloro-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-(2-fluorophenyl)-7-chloro-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3R)-1,3-dihydro-1-methyl-2-oxo-5-(2-fluorophenyl)-7-chloro-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2S,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-7-chloro-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-(2-fluorophenyl)-7-chloro-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(4-fluorophenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-(4-fluorophenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

```
Amendment & Response - Docket No. DM-7076-A
Serial No.: 09/505,788
```

Date: April 10, 2002

(2R,3S) N1-[(3R)-1,3-dihydro-1-methyl-2-oxo-5-(4-fluorophenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(pyrid-2-yl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(N-morpholino)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(dimethylamino)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(N-methyl-N-phenylamino)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(N-piperidinyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide:

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(N-homopiperidinyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(3-methoxyphenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(pyrid-4-yl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

```
Amendment & Response – Docket No. DM-7076-A
```

Serial No.: 09/505,788 Date: April 10, 2002

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-phenyl-7-methoxy-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(pyrid-3-yl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(cyclopropylmethyl)-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(3-fluorophenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-(3-fluorophenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3R)-1,3-dihydro-1-methyl-2-oxo-5-(3-fluorophenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)3-(3-buten-1-yl)-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(cyclopentylethyl)-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-(4-trifluoromethylphenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(3-buten-1-yl)-butanediamide;

```
Amendment & Response - Docket No. DM-7076-A Serial No.: 09/505,788
```

Date: April 10, 2002

(2R,3S) N1-[(3R)-1,3-dihydro-1-methyl-2-oxo-5-(4-trifluoromethylphenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(3-buten-1-yl)-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(4-trifluoromethylphenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-(4-trifluoromethylphenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3R)-1,3-dihydro-1-methyl-2-oxo-5-(4-trifluoromethylphenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-(4-trifluoromethylphenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-n-butyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-(4-trifluoromethylphenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-(4-chlorophenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(3-buten-1-yl)-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-(4-chlorophenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-n-butyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-N4-[benzyl]-butanediamide;

Serial No.: 09/505,788 Date: April 10, 2002

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-methyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-n-butyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(2-methylpropyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-(4-chlorophenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-ethyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-propyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[1,3-dihydro-1-(isopropyl)-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;

(2R,3S) N1-[(3S)-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3,3-diallyl-butanediamide;

[(2R,3S) N1-[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-allyl-butanediamide;] and

(2R,3S) N1-[1,3,4,5-tetrahydro-1,5-dimethyl-2,4-dioxo-2H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide.

12. (Amended) A compound, according to Claim 1, of Formula (Ia"):

Serial No.: 09/505,788 Date: April 10, 2002

or a pharmaceutically acceptable salt thereof, wherein:

Z is C₁-C₈ alkyl substituted with 1-3 R¹²;
 C₂-C₄ alkenyl substituted with 1-3 R¹²;
 C₂-C₄ alkynyl substituted with 1-3 R¹²;
 C₆-C₁₀ aryl substituted with 0-4 R^{12b};
 C₃-C₁₀ carbocycle substituted with 0-4 R^{12b}; or
 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{12b};

provided, when R^{13} is H, then Z is C_4 - C_8 alkyl substituted with 1-3 R^{12} ; C_2 - C_4 alkenyl substituted with 1-3 R^{12} ; or C_2 - C_4 alkynyl substituted with 1-3 R^{12} ; and

provided, when ring B is a 1,3,4,5-tetrahydro-1-(Z)-5-(R^{10})-6,6,7,7-tetra(R^{11})-2,4-dioxo-2H-1,5-diazepin-3-yl core, and R^{13} is H; then

 R^{10} is H, $C(=0)R^{17}$, $C(=0)OR^{17}$, $C(=0)NR^{18}R^{19}$, $S(=0)_2NR^{18}R^{19}$, $S(=0)_2R^{17}$; or C_1-C_6 alkyl optionally substituted with 0-3 R^{10a} ; and

 R^{10a} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, OR^{14} , Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$, and CF_3 .

Serial No.: 09/505,788 Date: April 10, 2002

13. (Amended) A compound according to Claim 12 of Formula (Ia")

or a pharmaceutically acceptable salt thereof,
wherein:

$$\begin{array}{l} {\rm R}^3 \ \ {\rm is} \ - ({\rm CR}^7{\rm R}^{7a})_{\,n} - {\rm R}^4\,, \\ \\ - ({\rm CR}^7{\rm R}^{7a})_{\,n} - {\rm S} - ({\rm CR}^7{\rm R}^{7a})_{\,m} - {\rm R}^4\,, \\ \\ - ({\rm CR}^7{\rm R}^{7a})_{\,n} - {\rm O} - ({\rm CR}^7{\rm R}^{7a})_{\,m} - {\rm R}^4\,, \ \ {\rm or} \\ \\ - ({\rm CR}^7{\rm R}^{7a})_{\,n} - {\rm N}\,({\rm R}^{7b}) - ({\rm CR}^7{\rm R}^{7a})_{\,m} - {\rm R}^4\,; \end{array}$$

n is 0, 1, or 2;

m is 0, 1, or 2;

R^{3a} is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, allyl, or 3-buten-1-yl;

 R^4 is H, OH, OR^{14a} ,

 C_1-C_6 alkyl substituted with 0-3 R^{4a} ,

 C_2 - C_6 alkenyl substituted with 0-3 R^{4a} ,

 C_2 - C_6 alkynyl substituted with 0-3 R^{4a} ,

 C_3-C_{10} carbocycle substituted with 0-3 R^{4b} ,

 C_6-C_{10} aryl substituted with 0-3 R^{4b} , or

5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3-R4b;

 R^{4a} , at each occurrence, is independently selected from [is] H, F, Cl, Br, I, CF_3 ,

Serial No.: 09/505,788 Date: April 10, 2002

 $\text{C}_3\text{-C}_{10}$ carbocycle substituted with 0-3 $\text{R}^{4\text{b}},$ $\text{C}_6\text{-C}_{10}$ aryl substituted with 0-3 $\text{R}^{4\text{b}},$ or

- 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{4b} ;
- R^{4b} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, and C_1-C_4 haloalkoxy;

 R^5 is H, OR^{14} ;

 C_1-C_6 alkyl substituted with 0-3 R^{5b} ;

 C_1-C_6 alkoxy substituted with 0-3 R^{5b} ;

 C_2 - C_6 alkenyl substituted with 0-3 R^{5b} ;

 C_2-C_6 alkynyl substituted with 0-3 R^{5b} ;

 C_3-C_{10} carbocycle substituted with 0-3 R^{5c} ;

 C_6-C_{10} aryl substituted with 0-3 R^{5c} ; or

5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{5c};

 R^{5a} is H or C_1-C_4 alkyl;

 $\ensuremath{\mathsf{R}^{5b}}\xspace,$ at each occurrence, is independently selected from:

H, C_1 - C_6 alkyl, CF_3 , OR^{14} , Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$;

 C_3-C_{10} carbocycle substituted with 0-3 R^{5c} ;

 C_6-C_{10} aryl substituted with 0-3 R^{5c} ; or

5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{5c};

Serial No.: 09/505,788 Date: April 10, 2002

 R^{5c} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, and C_1-C_4 haloalkoxy;

R⁶ is H, methyl, or ethyl;

- $\mbox{R}^{7},$ at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO2, CF3, phenyl, and C1-C4 alkyl;
- R^{7a} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , CF_3 , and C_1 - C_4 alkyl;
- ${\bf R}^{7b}$ is independently selected from H, methyl, ethyl, propyl, and butyl;

Ring B is selected from

[a 7 membered lactam or thiolactam,

wherein the lactam or thiolactam is saturated, partially saturated or unsaturated;

wherein each additional lactam carbon or thiolactam carbon is substituted with 0-2 R^{11} ; and,

optionally, the lactam or thiolactam contains a heteroatom selected from, -O-, -S-, -S(=O)-, -S(=O)₂-, -N=, -NH-, and -N(R¹⁰)-;

additionally, two R^{11} substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-3 R^{13} ;

Serial No.: 09/505,788 Date: April 10, 2002

additionally, two R¹¹ substituents on adjacent atoms may be combined to form a 5 to 6 membered heteroaryl fused radical, wherein said 5 to 6 membered heteroaryl fused radical comprises 1 or 2 heteroatoms selected from N, O, and S; wherein said 5 to 6 membered heteroaryl fused radical is substituted with 0-3 R¹³;

- additionally, two R^{11} substituents on the same or adjacent carbon atoms may be combined to form a C_3 - C_6 carbocycle substituted with 0-3 R^{13} ;
- R¹⁰ is H, C(=0)R¹⁷, C(=0)OR¹⁷, C(=0)NR¹⁸R¹⁹, S(=0)₂NR¹⁸R¹⁹, S(=0)₂R¹⁷;

 C₁-C₆ alkyl optionally substituted with 0-2 R^{10a};

 C₆-C₁₀ aryl substituted with 0-4 R^{10b};

 C₃-C₁₀ carbocycle substituted with 0-3 R^{10b}; or

 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{10b};
- R^{10a} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, OR^{14} , Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-4 R^{10b} ;
- R^{10b} , at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, C_1 - C_4 alkoxy, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, or CF_3 ;
- R¹¹, at each occurrence, is independently selected from H, C₁-C₄ alkoxy, Cl, F, Br, I, **[=0,]** CN, NO₂, NR¹⁸R¹⁹, C(=0)R¹⁷, C(=0)OR¹⁷, C(=0)NR¹⁸R¹⁹, S(=0)₂NR¹⁸R¹⁹, CF₃; C₁-C₆ alkyl optionally substituted with 0-3 R^{11a}; C₆-C₁₀ aryl substituted with 0-3 R^{11b}; C₃-C₁₀ carbocycle substituted with 0-3 R^{11b}; or

Serial No.: 09/505,788 Date: April 10, 2002

5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{11b};

- R^{11a} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, OR^{14} , Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-3 R^{11b} ;
- R^{11b} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=O)CH_3$, $S(=O)_2CH_3$, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, and C_1-C_4 haloalkoxy;
- Z is C₁-C₆ alkyl substituted with 1-3 R¹²;
 C₂-C₄ alkenyl substituted with 1-3 R¹²;
 C₂-C₄ alkynyl substituted with 1-3 R¹²;
 C₆-C₁₀ aryl substituted with 0-4 R^{12b};
 C₃-C₁₀ carbocycle substituted with 0-4 R^{12b}; or
 5 to 10 membered heterocycle containing 1 to 4
 heteroatoms selected from nitrogen, oxygen, and
 substituted with 0-3 R^{12b};
- R^{12} , at each occurrence, is independently selected from C_6 - C_{10} aryl substituted with 0-4 R^{12b} ; C_3 - C_{10} carbocycle substituted with 0-4 R^{12b} ; or 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{12b} ;
- R^{12b} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, and C_1-C_4 haloalkoxy;

Amendment & Response – Docket No. DM-7076-A Serial No.: 09/505,788

Date: April 10, 2002

- R^{13} , at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, C_1 - C_4 alkoxy, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, and CF_3 ;
- R^{14} is H, phenyl, benzyl, C_1 - C_6 alkyl, or C_2 - C_6 alkoxyalkyl;
- R^{14a} is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;
- R^{15} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, benzyl, phenethyl, $(C_1-C_6$ alkyl)-C(=0)-, and $(C_1-C_6$ alkyl)-S(=0)₂-;
- R^{16} , at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, benzyl, phenethyl, $(C_1$ - C_6 alkyl)-C(=0)-, and $(C_1$ - C_6 alkyl)- $S(=0)_2$ -;
- R^{17} is H, C_1 - C_6 alkyl, C_2 - C_6 alkoxyalkyl, aryl substituted by 0-4 R^{17a} , or -CH₂-aryl substituted by 0-4 R^{17a} ;
- R^{17a} is H, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, -OH, F, Cl, Br, I, CF₃, OCF₃, SCH₃, S(O)CH₃, SO₂CH₃, -NH₂, -N(CH₃)₂, or C₁-C₄ haloalkyl;
- R^{18} , at each occurrence, is independently selected from H, C_1 - C_6 alkyl, phenyl, benzyl, phenethyl, $(C_1$ - C_6 alkyl)-C(=0)-, and $(C_1$ - C_6 alkyl)- $S(=0)_2$ -; and
- R¹⁹, at each occurrence, is independently selected from H, OH, C_1 - C_6 alkyl, phenyl, benzyl, phenethyl, $(C_1$ - C_6 alkyl)-C(=0)-, and $(C_1$ - C_6 alkyl)-S(=0) $_2$ -;

provided, when R^{13} is H, then Z is C_4 - C_6 alkyl substituted with 1-3 R^{12} ; C_2 - C_4 alkenyl substituted with 1-3 R^{12} ; or C_2 - C_4 alkynyl substituted with 1-3 R^{12} .

Serial No.: 09/505,788 Date: April 10, 2002

14. (Amended) A compound according to Claim 13 of Formula (Ia<u>"</u>)

or a pharmaceutically acceptable salt thereof, wherein:

 R^3 is $-(CHR^7)_n-R^4$,

n is 0 or 1;

R^{3a} is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, allyl, or 3-buten-1-yl;

 R^4 is H, OH, OR^{14a} ,

 C_1-C_4 alkyl substituted with 0-2 R^{4a} ,

 C_2 - C_4 alkenyl substituted with 0-2 R^{4a} ,

 $C_2\text{-}C_4$ alkynyl substituted with 0-1 R^{4a} ,

 C_3 - C_6 carbocycle substituted with 0-3 R^{4b} ,

 C_6-C_{10} aryl substituted with 0-3 R^{4b} , or

5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{4b} ;

 ${\rm R^{4a}},$ at each occurrence, is independently selected from [is] H, F, Cl, Br, I, CF3,

 C_3 - C_6 carbocycle substituted with 0-3 R^{4b} ,

phenyl substituted with 0-3 R4b, or

5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and

Serial No.: 09/505,788 Date: April 10, 2002

sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{4b} ;

 R^{4b} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_4 alkyl, C_1-C_3 alkoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;

 R^5 is H, OR^{14} ;

 C_1-C_4 alkyl substituted with 0-3 R^{5b} ; C_2-C_4 alkenyl substituted with 0-3 R^{5b} ; C_2-C_4 alkynyl substituted with 0-3 R^{5b} ;

R^{5a} is H, methyl, ethyl, propyl, or butyl;

 R^{5b} , at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, CF_3 , OR^{14} , Cl, F, Br, I, =0;

 C_3-C_6 carbocycle substituted with 0-3 R^{5c} ; phenyl substituted with 0-3 R^{5c} ; or

5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{5c};

 R^{5c} , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_4 alkyl, C_1-C_3 alkoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;

R6 is H;

 R^7 , at each occurrence, is independently selected from H, F, CF₃, methyl, and ethyl;

Ring B is **selected from**

Serial No.: 09/505,788 Date: April 10, 2002

[a 7 membered lactam or thiolactam, wherein the lactam or thiolactam is saturated, partially saturated or unsaturated;

wherein each additional lactam carbon or thiolactam carbon is substituted with 0-2 R¹¹; and, optionally, the lactam or thiolactam contains a heteroatom selected from -N=, -NH-, and -N(R¹⁰)-;

- additionally, two R¹¹ substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-2 R¹³;
- additionally, two R¹¹ substituents on adjacent atoms may be combined to form a 5 to 6 membered heteroaryl fused radical, wherein said 5 to 6 membered heteroaryl fused radical comprises 1 or 2 heteroatoms selected from N, O, and S; wherein said 5 to 6 membered heteroaryl fused radical is substituted with 0-2 R¹³;
- additionally, two R^{11} substituents on the same or adjacent carbon atoms may be combined to form a C_3 - C_6 carbocycle substituted with 0-2 R^{13} ;
- R¹⁰ is H, C(=0)R¹⁷, C(=0)OR¹⁷;

 C₁-C₄ alkyl optionally substituted with 0-1 R^{10a};

 phenyl substituted with 0-4 R^{10b};

 C₃-C₆ carbocycle substituted with 0-3 R^{10b}; or

 5 to 6 membered heterocycle containing 1 to 4

 heteroatoms selected from nitrogen, oxygen, and

Serial No.: 09/505,788 Date: April 10, 2002

sulphur, wherein said 5 to 6 membered heterocycle is substituted with $0-3 \ R^{10b}$;

- R^{10a} [, at each occurrence,] is [independently] selected from H, C_1 - C_4 alkyl, OR^{14} , Cl, F, Br, I, =0, CN, NO_2 , $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-4 R^{10b} ;
- R^{10b} , at each occurrence, is independently selected from H, OH, C_1 - C_4 alkyl, C_1 - C_3 alkoxy, Cl, F, Br, I, CN, NO_2 , $NR^{15}R^{16}$, or CF_3 ;
- R^{11} [, at each occurrence,] is [independently] selected from H, C_1 - C_4 alkoxy, C_1 , C_1 , C_1 , C_2 , C_3 ;

 C_1-C_6 alkyl optionally substituted with 0-3 R^{11a} ;

C₆-C₁₀ aryl substituted with 0-3 R^{11b};

C₃-C₆ carbocycle substituted with 0-3 R^{11b}; or

- 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{11b} ;
- R^{11a} , at each occurrence, is independently selected from H, C_1-C_4 alkyl, OR^{14} , F, =0, $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-3 R^{11b} ;
- R^{11b} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , C_1-C_4 alkyl, C_1-C_3 alkoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- Z is C_1-C_4 alkyl substituted with 1-3 R^{12} ;

 C_2-C_4 alkenyl substituted with 1-3 R^{12} ;

 C_2-C_4 alkynyl substituted with 1-3 R^{12} ;

 C_6-C_{10} aryl substituted with 0-4 R^{12b} ;

C₃-C₆ carbocycle substituted with 0-4 R^{12b}; or

5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and

Serial No.: 09/505,788 Date: April 10, 2002

sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{12b};

- R¹², at each occurrence, is independently selected from C₆-C₁₀ aryl substituted with 0-4 R^{12b}; C₃-C₆ carbocycle substituted with 0-4 R^{12b}; or 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R^{12b};
- R^{12b} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, C_1-C_4 alkyl, C_1-C_3 alkoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- $\rm R^{13},$ at each occurrence, is independently selected from H, OH, C1-C6 alkyl, C1-C4 alkoxy, Cl, F, Br, I, CN, NO2, NR^{15}R^{16}, and CF3;
- R^{14} is H, phenyl, benzyl, C_1-C_4 alkyl, or C_2-C_4 alkoxyalkyl;
- R^{15} , at each occurrence, is independently selected from H, C_1 - C_4 alkyl, benzyl, phenethyl, $(C_1-C_4$ alkyl)-C(=0)-, and $(C_1-C_4$ alkyl)-S(=0)₂-;
- R^{16} , at each occurrence, is independently selected from H, OH, C_1 - C_4 alkyl, benzyl, phenethyl, $(C_1$ - C_4 alkyl)-C(=0)-, and $(C_1$ - C_4 alkyl)-S(=0)₂-;
- R¹⁷ is H, methyl, ethyl, propyl, butyl, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, phenyl substituted by 0-3 R^{17a}, or -CH₂-phenyl substituted by 0-3 R^{17a};
- R^{17a} is H, methyl, methoxy, -OH, F, Cl, CF₃, or OCF₃;

Serial No.: 09/505,788 Date: April 10, 2002

R¹⁸, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and

 R^{19} , at each occurrence, is independently selected from H, methyl, and ethyl;

provided, when R^{13} is H, then Z is butyl substituted with 1-3 R^{12} ; C_2 - C_4 alkenyl substituted with 1-3 R^{12} ; or C_2 - C_4 alkynyl substituted with 1-3 R^{12} .

16. (Twice Amended) A compound according to Claim 14 [15] of
 Formula (Ic):

$$H_2N$$
 R^5
 H
 N
 Z
 R^{13}
 R^{13}

(Ic)

or a pharmaceutically acceptable salt thereof wherein

 R^3 is R^4 ,

 R^4 is C_1 - C_4 alkyl substituted with 0-1 R^{4a} , C_2 - C_4 alkenyl substituted with 0-1 R^{4a} , or C_2 - C_4 alkynyl substituted with 0-1 R^{4a} ;

R^{4a}[, at each occurrence,] is [independently] selected from _____H, F, _CF₃, _____

C₃-C₆ carbocycle substituted with 0-3 R^{4b},
phenyl substituted with 0-3 R^{4b}, or
5 to 6 membered heterocycle containing 1 to 4
heteroatoms selected from nitrogen, oxygen, and

Serial No.: 09/505,788 Date: April 10, 2002

sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{4b}; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

- R^{4b} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R^5 is C_1 - C_4 alkyl substituted with 0-1 R^{5b} ; C_2 - C_4 alkenyl substituted with 0-1 R^{5b} ; C_2 - C_4 alkynyl substituted with 0-1 R^{5b} ;
- R^{5b}[, at each occurrence,] is [independently] selected from:
 H, methyl, ethyl, propyl, butyl, CF₃, OR¹⁴, =O;
 C₃-C₆ carbocycle substituted with 0-2 R^{5c};
 phenyl substituted with 0-3 R^{5c}; or
 5 to 6 membered heterocycle containing 1 to 4
 heteroatoms selected from nitrogen, oxygen, and
 sulphur, wherein said 5 to 6 membered heterocycle is
 substituted with 0-3 R^{5c}; wherein said 5 to 6 membered
 heterocycle is selected from pyridinyl, pyrimidinyl,
 triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl,
 piperazinyl, piperidinyl, pyrazolyl, imidazolyl,
 oxazolyl, isoxazolyl, and tetrazolyl;
- R^{5c} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R^{11} [, at each occurrence,] is [independently] selected from H, [=0,] $NR^{18}R^{19}$, CF_3 ; C_1 - C_4 alkyl optionally substituted with 0-1 R^{11a} ;

Serial No.: 09/505,788 Date: April 10, 2002

phenyl substituted with 0-3 R^{11b};
C₃-C₆ carbocycle substituted with 0-3 R^{11b}; or
5 to 6 membered heterocycle containing 1 to 4
heteroatoms selected from nitrogen, oxygen, and


heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{11b}; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

 R^{11a} [, at each occurrence,] is [independently] selected from H, C_1 - C_4 alkyl, OR^{14} , F, [Cl,] =0, $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-3 R^{11b} ;

 R^{11b} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1 - C_2 haloalkyl, and C_1 - C_2 haloalkoxy;

Z is C₁-C₃ alkyl substituted with 1-3 R¹²;
 C₂-C₃ alkenyl substituted with 1-3 R¹²;
 C₂-C₃ alkynyl substituted with 1-3 R¹²;
 C₆-C₁₀ aryl substituted with 0-4 R^{12b};
 C₃-C₆ carbocycle substituted with 0-3 R^{12b}; or
 5 to 6 membered heterocycle containing 1 to 4
 heteroatoms selected from nitrogen, oxygen, and
 sulphur, wherein said 5 to 6 membered heterocycle is
 substituted with 0-3 R^{12b}; wherein said 5 to 6
 membered heterocycle is selected from pyridinyl,
 pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl,
 pyrrolyl, piperazinyl, piperidinyl, pyrazolyl,
 imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

 R^{12} , at each occurrence, is independently selected from C_6-C_{10} aryl substituted with 0-4 R^{12b} ; C_3-C_6 carbocycle substituted with 0-3 R^{12b} ; or



Serial No.: 09/505,788 Date: April 10, 2002

- 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{12b}; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
- R^{12b} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=O)CH_3$, $S(=O)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R^{13} , at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, Cl, F, Br, CN, $NR^{15}R^{16}$, and CF_3 ;
- R¹⁴ is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;
- R¹⁵, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;
- R^{16} , at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl, methyl-C(=O)-, ethyl-C(=O)-, methyl-S(=O)₂-, and ethyl-S(=O)₂-;
- R¹⁸, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and
- R¹⁹, at each occurrence, is independently selected from H, methyl, and ethyl;

provided, when R^{13} is H, then Z is C_2-C_3 alkenyl substituted with 1-3 R^{12} ; or

Serial No.: 09/505,788 Date: April 10, 2002

 C_2-C_3 alkynyl substituted with 1-3 R^{12} .

18. (Twice Amended) A compound according to Claim 14 [15] of Formula (Ie):

$$H_2N$$
 R^5
 H
 O
 N
 Z
 R^{13}
 R^{13}

or a pharmaceutically acceptable salt thereof wherein:

 R^3 is R^4 ,

 R^4 is C_1 - C_4 alkyl substituted with 0-1 R^{4a} , C_2 - C_4 alkenyl substituted with 0-1 R^{4a} , or C_2 - C_4 alkynyl substituted with 0-1 R^{4a} ;

 R^{4a} [, at each occurrence,] is [independently] selected from H, F, CF_3 ,

 C_3-C_6 carbocycle substituted with 0-3 R^{4b} , phenyl substituted with 0-3 R^{4b} , or

- 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{4b}; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
- R^{4b} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;

Amendment & Response – Docket No. DM-7076-A Serial No.: 09/505,788 Date: April 10, 2002

 R^5 is C_1-C_4 alkyl substituted with 0-1 R^{5b} ; C_2-C_4 alkenyl substituted with 0-1 R^{5b} ; C_2-C_4 alkynyl substituted with 0-1 R^{5b} ;

R^{5b}[, at each occurrence,] is [independently] selected from:

H, methyl, ethyl, propyl, butyl, CF₃, OR¹⁴, =0;

C₃-C₆ carbocycle substituted with 0-2 R^{5c};

phenyl substituted with 0-3 R^{5c}; or

5 to 6 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 6 membered heterocycle is

substituted with 0-3 R^{5c}; wherein said 5 to 6 membered

heterocycle is selected from pyridinyl, pyrimidinyl,

triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl,

piperazinyl, piperidinyl, pyrazolyl, imidazolyl,

oxazolyl, isoxazolyl, and tetrazolyl;

- R^{5c} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R¹⁰ is H, C(=0)R¹⁷, C(=0)OR¹⁷;

 C₁-C₄ alkyl optionally substituted with 0-1 R^{10a};

 phenyl substituted with 0-4 R^{10b};

 C₃-C₆ carbocycle substituted with 0-3 R^{10b}; or

 5 to 6 membered heterocycle containing 1 to 4

 heteroatoms selected from nitrogen, oxygen, and

 sulphur, wherein said 5 to 6 membered heterocycle is

 substituted with 0-3 R^{10b}; wherein said 5 to 6

 membered heterocycle is selected from pyridinyl,

 pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl,

 pyrrolyl, piperazinyl, piperidinyl, pyrazolyl,

 imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

Serial No.: 09/505,788 Date: April 10, 2002

 R^{10a} [, at each occurrence,] is [independently] selected from H, methyl, ethyl, propyl, butyl, OR^{14} , Cl, F, =0, $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-4 R^{10b} ;

- R^{10b} , at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl, F, $NR^{15}R^{16}$, and CF_3 ;
- Z is C1-C3 alkyl substituted with 1-3 R¹²;
 C2-C3 alkenyl substituted with 1-3 R¹²;
 C2-C3 alkynyl substituted with 1-3 R¹²;
 C6-C10 aryl substituted with 0-4 R^{12b};
 C3-C6 carbocycle substituted with 0-3 R^{12b}; or
 5 to 6 membered heterocycle containing 1 to 4
 heteroatoms selected from nitrogen, oxygen, and
 sulphur, wherein said 5 to 6 membered heterocycle is
 substituted with 0-3 R^{12b}; wherein said 5 to 6
 membered heterocycle is selected from pyridinyl,
 pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl,
 pyrrolyl, piperazinyl, piperidinyl, pyrazolyl,
 imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
- R¹², at each occurrence, is independently selected from C₆-C₁₀ aryl substituted with 0-4 R^{12b};
 C₃-C₆ carbocycle substituted with 0-3 R^{12b}; or
 5 to 6 membered heterocycle containing 1 to 4
 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R^{12b}; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

 R^{12b} , at each occurrence, is independently selected from

Amendment & Response – Docket No. DM-7076-A Serial No.: 09/505,788 Date: April 10, 2002

H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;

- R^{13} , at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, Cl, F, Br, CN, $NR^{15}R^{16}$, and CF_3 ;
- R¹⁴ is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;
- R¹⁵, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;
- R¹⁶, at each occurrence, is independently selected from
 H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl,
 methyl-C(=0)-, ethyl-C(=0)-,
 methyl-S(=0)₂-, and ethyl-S(=0)₂-;
- R^{17} is H, methyl, ethyl, propyl, butyl, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, phenyl substituted by 0-3 R^{17a} , or $-CH_2$ -phenyl substituted by 0-3 R^{17a} ;
- R^{17a} is H, methyl, methoxy, -OH, F, Cl, CF₃, or OCF₃;
- R¹⁸, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and
- R¹⁹, at each occurrence, is independently selected from H, methyl, and ethyl;

provided, when R^{13} is H, then Z is C_2 - C_3 alkenyl substituted with 1-3 R^{12} ; or C_2 - C_3 alkynyl substituted with 1-3 R^{12} . Amendment & Response - Docket No. DM-7076-A Serial No.: 09/505,788

Date: April 10, 2002

20. (Twice Amended) A compound according to one of Claims 16, [17,] 18, or 26 [19,] wherein:

```
R^3 is -CH_3, -CH_2CH_3, -CH_2CH_2CH_3, -CH_2CH_2CH_2CH_3,
   -CH(CH_3)_2, -CH(CH_3)CH_2CH_3, -CH_2CH(CH_3)_2,
   -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>,
   -CH=CH_2, -CH_2CH=CH_2, -CH_2C(CH_3)=CH_2,
   -CH<sub>2</sub>CH<sub>2</sub>CH=CH<sub>2</sub>,
   cis-CH2CH=CH(CH3),
   trans-CH<sub>2</sub>CH=CH(CH<sub>3</sub>),
   -C \equiv CH, -CH_2C \equiv CH, -CH_2C \equiv C(CH_3),
   cyclopropyl-CH2-, cyclobutyl-CH2-, cyclopentyl-CH2-,
   cyclohexyl-CH2-, cyclopropyl-CH2CH2-,
   cyclobutyl-CH2CH2-, cyclopentyl-CH2CH2-,
   cyclohexyl-CH<sub>2</sub>CH<sub>2</sub>-, phenyl-CH<sub>2</sub>-,
    (2-F-pheny1)CH_2-, (3-F-pheny1)CH_2-, (4-F-pheny1)CH_2-,
    (2-Cl-phenyl)CH_2-, (3-Cl-phenyl)CH_2-, (4-Cl-phenyl)CH_2-,
    (2,3-diF-phenyl)CH<sub>2</sub>-, (2,4-diF-phenyl)CH<sub>2</sub>-,
    (2,5-diF-phenyl)CH<sub>2</sub>-, (2,6-diF-phenyl)CH<sub>2</sub>-,
    (3,4-diF-phenyl)CH<sub>2</sub>-, (3,5-diF-phenyl)CH<sub>2</sub>-,
    (2,3-diCl-phenyl)CH<sub>2</sub>-, (2,4-diCl-phenyl)CH<sub>2</sub>-,
    (2,5-diCl-phenyl)CH<sub>2</sub>-, (2,6-diCl-phenyl)CH<sub>2</sub>-,
    (3,4-diCl-phenyl)CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>-,
   (3-F-4-Cl-phenyl)CH<sub>2</sub>-, <math>(3-F-5-Cl-phenyl)CH<sub>2</sub>-,
    (3-Cl-4-F-phenyl)CH_2-, phenyl-CH_2CH_2-,
   (2-F-phenyl)CH_2CH_2-, (3-F-phenyl)CH_2CH_2-,
   (4-F-pheny1)CH<sub>2</sub>CH<sub>2</sub>-, (2-Cl-pheny1)CH<sub>2</sub>CH<sub>2</sub>-,
   (3-Cl-phenyl)CH_2CH_2-, (4-Cl-phenyl)CH_2CH_2-,
   (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
   (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
   (3,4-diF-phenyl)CH_2CH_2-, (3,5-diF-phenyl)CH_2CH_2-,
   (2,3-diCl-pheny1)CH<sub>2</sub>CH<sub>2</sub>-, (2,4-diCl-pheny1)CH<sub>2</sub>CH<sub>2</sub>-,
   (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
   (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
   (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, or <math>(3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
```

 R^5 is $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CH_2CH_2CH_3$,

Amendment & Response – Docket No. DM-7076-A Serial No.: 09/505,788

```
Date: April 10, 2002
    -CH(CH_3)CH_2CH_3, -CH_2CH(CH_3)_2, -CH_2C(CH_3)_3,
    -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH (CH<sub>3</sub>) CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH (CH<sub>3</sub>) CH<sub>2</sub>CH<sub>3</sub>,
    -CH_2CH_2CH(CH_3)_2, -CH(CH_2CH_3)_2, -CH_2CF_3, -CH_2CH_2CF_3,
    -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, -CH=CH<sub>2</sub>, -CH<sub>2</sub>CH=CH<sub>2</sub>,
    -CH=CHCH<sub>3</sub>, cis-CH<sub>2</sub>CH=CH(CH<sub>3</sub>), trans-CH<sub>2</sub>CH=CH(CH<sub>3</sub>),
    trans-CH<sub>2</sub>CH=CH(C<sub>6</sub>H<sub>5</sub>), -CH<sub>2</sub>CH=C(CH<sub>3</sub>)<sub>2</sub>, cis-CH<sub>2</sub>CH=CHCH<sub>2</sub>CH<sub>3</sub>,
    trans-CH<sub>2</sub>CH=CHCH<sub>2</sub>CH<sub>3</sub>, cis-CH<sub>2</sub>CH<sub>2</sub>CH=CH(CH<sub>3</sub>),
    trans-CH<sub>2</sub>CH<sub>2</sub>CH=CH(CH<sub>3</sub>), trans-CH<sub>2</sub>CH=CHCH<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>),
    -C \equiv CH, -CH_2C \equiv CH, -CH_2C \equiv C(CH_3), -CH_2C \equiv C(C_6H_5),
    -CH_2CH_2C \equiv CH, -CH_2CH_2C \equiv C(CH_3), -CH_2CH_2C \equiv C(C_6H_5),
    cyclopropyl-CH2-, cyclobutyl-CH2-, cyclopentyl-CH2-,
    cyclohexyl-CH<sub>2</sub>-, (2-CH<sub>3</sub>-cyclopropyl)CH<sub>2</sub>-,
    (3-CH_3-cyclobuty1)CH_2-,
    cyclopropyl-CH<sub>2</sub>CH<sub>2</sub>-, cyclobutyl-CH<sub>2</sub>CH<sub>2</sub>-,
    cyclopentyl-CH2CH2-, cyclohexyl-CH2CH2-,
    (2-CH<sub>3</sub>-cyclopropyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-CH<sub>3</sub>-cyclobutyl)CH<sub>2</sub>CH<sub>2</sub>-,
    phenyl-CH_2-, (2-F-phenyl)CH_2-, (3-F-phenyl)CH_2-,
    (4-F-phenyl)CH<sub>2</sub>-, furanyl-CH<sub>2</sub>-, thienyl-CH<sub>2</sub>-,
    pyridyl-CH<sub>2</sub>-, 1-imidazolyl-CH<sub>2</sub>-, oxazolyl-CH<sub>2</sub>-,
    isoxazolyl-CH<sub>2</sub>-,
    phenyl-CH_2CH_2-, (2-F-phenyl)CH_2CH_2-, (3-F-phenyl)CH_2CH_2-,
    (4-F-phenyl)CH_2CH_2-, furanyl-CH_2CH_2-, thienyl-CH_2CH_2-,
    pyridyl-CH<sub>2</sub>CH<sub>2</sub>-, 1-imidazolyl-CH<sub>2</sub>CH<sub>2</sub>-, oxazolyl-CH<sub>2</sub>CH<sub>2</sub>-,
    isoxazolyl-CH<sub>2</sub>CH<sub>2</sub>-;
Z is phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl,
    2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-dif-phenyl,
    2,4-dif-phenyl, 2,5-dif-phenyl, 2,6-dif-phenyl,
    3,4-diF-phenyl, 3,5-diF-phenyl, 2,3-diCl-phenyl,
    2,4-diCl-phenyl, 2,5-diCl-phenyl, 2,6-diCl-phenyl,
    3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl,
    3-F-5-Cl-phenyl, 3-Cl-4-F-phenyl, 2-MeO-phenyl,
   3-MeO-phenyl, 4-MeO-phenyl, 2-Me-phenyl, 3-Me-phenyl,
    4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl,
   2-CF<sub>3</sub>O-phenyl, 3-CF<sub>3</sub>O-phenyl, 4-CF<sub>3</sub>O-phenyl,
```

furanyl, thienyl, pyridyl, 2-Me-pyridyl, 3-Me-pyridyl,
 4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl,

Serial No.: 09/505,788 Date: April 10, 2002 cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-piperidinyl, phenyl-CH₂-, (2-F-phenyl)CH₂-, (3-F-phenyl)CH₂-, $(4-F-pheny1)CH_2-$, $(2-Cl-pheny1)CH_2-$, $(3-Cl-pheny1)CH_2-$, $(4-F-pheny1)CH_2-$, $(4-F-pheny1)CH_2 Cl-phenyl)CH_2-$, $(2,3-diF-phenyl)CH_2-$, (2,4-diF-pheny1)CH₂-, (2,5-diF-pheny1)CH₂-,(2,6-diF-pheny1)CH₂-, (3,4-diF-pheny1)CH₂-,(3,5-diF-phenyl)CH₂-, (2,3-diCl-phenyl)CH₂-,(2,4-diCl-phenyl)CH₂-, (2,5-diCl-phenyl)CH₂-,(2,6-diCl-phenyl)CH₂-, (3,4-diCl-phenyl)CH₂-,(3,5-diCl-phenyl)CH₂-, (3-F-4-Cl-phenyl)CH₂-,(3-F-5-Cl-phenyl)CH₂-, (3-Cl-4-F-phenyl)CH₂-, $(2-MeO-phenyl)CH_2-, (3-MeO-phenyl)CH_2-,$ (4-MeO-pheny1)CH₂-, (2-Me-pheny1)CH₂-,(3-Me-pheny1)CH₂-, (4-Me-pheny1)CH₂-, $(2-MeS-pheny1)CH_2-, (3-MeS-pheny1)CH_2-,$ 4-MeS-phenyl)CH₂-, (2-CF₃O-phenyl)CH₂-, $(3-CF_3O-phenyl)CH_2-$, $(4-CF_3O-phenyl)CH_2-$, (furanyl)CH₂-, (thienyl)CH₂-, (pyridyl)CH₂-, $(2-Me-pyridy1)CH_2-, (3-Me-pyridy1)CH_2-,$ (4-Me-pyridyl)CH₂-, (1-imidazolyl)CH₂-,(oxazolyl)CH₂-, (isoxazolyl)CH₂-, $(cyclopropyl)CH_{2}-, (cyclobutyl)CH_{2}-, (cyclopentyl)CH_{2}-,$ (cyclohexyl)CH₂-, (N-piperidinyl)CH₂-, phenyl-CH₂CH₂-, (phenyl)₂CHCH₂-, (2-F-phenyl)CH₂CH₂-, (3-F-pheny1)CH₂CH₂-, (4-F-pheny1)CH₂CH₂-, $(2-Cl-phenyl)CH_2CH_2-, (3-Cl-phenyl)CH_2CH_2-,$ (4-Cl-phenyl)CH₂CH₂-, (2,3-diF-phenyl)CH₂CH₂-,(2,4-diF-phenyl)CH₂CH₂-, (2,5-diF-phenyl)CH₂CH₂-,(2,6-diF-phenyl)CH₂CH₂-, (3,4-diF-phenyl)CH₂CH₂-,(3,5-diF-phenyl)CH₂CH₂-, (2,3-diCl-phenyl)CH₂CH₂-,(2, 4-diCl-phenyl) CH₂CH₂-, (2, 5-diCl-phenyl) CH₂CH₂-,(2,6-diCl-phenyl)CH₂CH₂-, (3,4-diCl-phenyl)CH₂CH₂-,(3,5-diCl-phenyl)CH₂CH₂-, (3-F-4-Cl-phenyl)CH₂CH₂-,(3-F-5-C1-pheny1)CH₂CH₂-, <math>(3-C1-4-F-pheny1)CH₂CH₂-,(2-MeO-pheny1)CH₂CH₂-, (3-MeO-pheny1)CH₂CH₂-,

Amendment & Response - Docket No. DM-7076-A

```
Date: April 10, 2002
     (4-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
     (3-Me-pheny1)CH<sub>2</sub>CH<sub>2</sub>-, (4-Me-pheny1)CH<sub>2</sub>CH<sub>2</sub>-,
     (2-MeS-phenyl)CH_2CH_2-, (3-MeS-phenyl)CH_2CH_2-,
     (4-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
     (3-CF_3O-pheny1)CH_2CH_2-, (4-CF_3O-pheny1)CH_2CH_2-,
        (furanyl)CH<sub>2</sub>CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,
     (2-Me-pyridyl) CH<sub>2</sub>CH<sub>2</sub>-, (3-Me-pyridyl) CH<sub>2</sub>CH<sub>2</sub>-,
     (4-Me-pyridyl)CH_2CH_2-, (imidazolyl)CH_2CH_2-,
        (oxazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>CH<sub>2</sub>-,
        (cyclopropyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclobutyl)CH<sub>2</sub>CH<sub>2</sub>-,
        (cyclopentyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclohexyl)CH<sub>2</sub>CH<sub>2</sub>-, or
        (N-piperidinyl)CH<sub>2</sub>CH<sub>2</sub>-;
R<sup>10</sup> is H, methyl, ethyl, phenyl, benzyl, phenethyl,
    4-F-phenyl, (4-F-phenyl)CH<sub>2</sub>-, <math>(4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
    4-Cl-phenyl, (4-Cl-phenyl)CH<sub>2</sub>-, <math>(4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
    4-CH_3-pheny1, (4-CH_3-pheny1)CH_2-, (4-CH_3-pheny1)CH_2CH_2-,
    4-CF_3-phenyl, (4-CF_3-phenyl)CH_2-, or
    (4-CF_3-phenyl)CH_2CH_2-;
R<sup>11</sup>, at each occurrence, is independently selected from
    H, =0, methyl, ethyl, phenyl, benzyl, phenethyl,
    4-F-phenyl, (4-F-phenyl)CH<sub>2</sub>-, <math>(4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
    3-F-pheny1, (3-F-pheny1)CH<sub>2</sub>-, <math>(3-F-pheny1)CH<sub>2</sub>CH<sub>2</sub>-,
    2-F-pheny1, (2-F-pheny1)CH<sub>2</sub>-, <math>(2-F-pheny1)CH<sub>2</sub>CH<sub>2</sub>-,
    4-Cl-phenyl, (4-Cl-phenyl)CH<sub>2</sub>-, <math>(4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,
    3-Cl-phenyl, (3-Cl-phenyl)CH_2-, (3-Cl-phenyl)CH_2CH_2-,
    4-CH_3-phenyl, (4-CH_3-phenyl)CH_2-, (4-CH_3-phenyl)CH_2CH_2-,
    3-CH_3-pheny1, (3-CH_3-pheny1)CH_2-, (3-CH_3-pheny1)CH_2CH_2-,
    4-CF_3-phenyl, (4-CF_3-phenyl)CH_2-, (4-CF_3-phenyl)CH_2CH_2-,
    pyrid-2-yl, pyrid-3-yl, or pyrid-4-yl, and
R<sup>13</sup>, at each occurrence, is independently selected from
```

Serial No.: 09/505,788

H, F, C1, OH, $-CH_3$, $-CH_2CH_3$, $-OCH_3$, or $-CF_3$.

Serial No.: 09/505,788 Date: April 10, 2002

22. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

- 23. (Amended) A method for the treatment of <u>Alzheimer's</u> <u>Disease</u> [neurological disorders associated with β -amyloid] production comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of Claim 1.
- 25. (New) A compound according to Claim 4 of Formula (Ig):

(Iq)

or a pharmaceutically acceptable salt thereof wherein:

 \mathbb{R}^3 is \mathbb{R}^4 ,

 R^4 is C_1-C_4 alkyl substituted with 0-1 R^{4a} , C_2-C_4 alkenyl substituted with 0-1 R^{4a} , or C_2-C_4 alkynyl substituted with 0-1 R^{4a} ;

R4a, at each occurrence, is independently selected from H, F, CF₃,

C₃-C₆ carbocycle substituted with 0-3 R^{4b}, phenyl substituted with 0-3 R^{4b}, or

5 to 6 membered heterocycle containing 1 to 4
heteroatoms selected from nitrogen, oxygen, and
sulphur, wherein said 5 to 6 membered heterocycle is
substituted with 0-3 R4b; wherein said 5 to 6 membered
heterocycle is selected from pyridinyl, pyrimidinyl,
triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl,

Serial No.: 09/505,788 Date: April 10, 2002

piperazinyl, piperidinyl, pyrazolyl, imidazolyl,
oxazolyl, isoxazolyl, and tetrazolyl;

- R^{4b} , at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R^5 is C_1-C_4 alkyl substituted with 0-1 R^{5b} ; C_2-C_4 alkenyl substituted with 0-1 R^{5b} ; C_2-C_4 alkynyl substituted with 0-1 R^{5b} ;

R^{5b} is selected from:

H, methyl, ethyl, propyl, butyl, CF_3 , OR^{14} , =0; C_3-C_6 carbocycle substituted with 0-2 R^{5c} ; phenyl substituted with 0-3 R^{5c} ; or

- 5 to 6 membered heterocycle containing 1 to 4
 heteroatoms selected from nitrogen, oxygen, and
 sulphur, wherein said 5 to 6 membered heterocycle is
 substituted with 0-3 R^{5c}; wherein said 5 to 6 membered
 heterocycle is selected from pyridinyl, pyrimidinyl,
 triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl,
 piperazinyl, piperidinyl, pyrazolyl, imidazolyl,
 oxazolyl, isoxazolyl, and tetrazolyl;
- R^{5c}, at each occurrence, is independently selected from H, OH, Cl, F, NR¹⁵R¹⁶, CF₃, acetyl, SCH₃, S(=0)CH₃, S(=0)₂CH₃, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1 - C_2 haloalkyl, and C_1 - C_2 haloalkoxy;
- R¹⁰ is H, C(=0)R¹⁷, C(=0)OR¹⁷;

 C₁-C₄ alkyl optionally substituted with 0-1 R^{10a};

 phenyl substituted with 0-4 R^{10b};

 C₃-C₆ carbocycle substituted with 0-3 R^{10b}; or

 5 to 6 membered heterocycle containing 1 to 4

 heteroatoms selected from nitrogen, oxygen, and
 sulphur, wherein said 5 to 6 membered heterocycle is

Serial No.: 09/505,788 Date: April 10, 2002

substituted with 0-3 R^{10b}; wherein said 5 to 6
membered heterocycle is selected from pyridinyl,
pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl,
pyrrolyl, piperazinyl, piperidinyl, pyrazolyl,
imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

- R^{10a} is selected from H, methyl, ethyl, propyl, butyl, OR^{14} , Cl, F, =0, $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-4 R^{10b} ;
- R^{10b}, at each occurrence, is independently selected from H,

 OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy,

 propoxy, Cl, F, NR¹⁵R¹⁶, and CF₃;

Z is H;

 $\underline{C_1}$ - $\underline{C_4}$ alkyl substituted with 0-3 $\underline{R^{12a}}$; $\underline{C_2}$ - $\underline{C_4}$ alkenyl substituted with 0-3 $\underline{R^{12a}}$; or $\underline{C_2}$ - $\underline{C_4}$ alkynyl substituted with 0-3 $\underline{R^{12a}}$;

- R^{12a}, at each occurrence, is independently selected from H, OH, Cl, F, $NR^{15}R^{16}$, CF_3 , acetyl, SCH_3 , $S(=0)CH_3$, $S(=0)_2CH_3$, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R¹³, at each occurrence, is independently selected from

 H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy,
 Cl, F, Br, CN, NR¹⁵R¹⁶, and CF₃;
- R¹⁴ is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;
- R¹⁵, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;
- R¹⁶, at each occurrence, is independently selected from

 H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl,

 methyl-C(=0)-, ethyl-C(=0)-,

 methyl-S(=0)₂-, and ethyl-S(=0)₂-;

Serial No.: 09/505,788 Date: April 10, 2002

R¹⁷ is H, methyl, ethyl, propyl, butyl, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, phenyl substituted by 0-3 R^{17a}, or -CH₂-phenyl substituted by 0-3 R^{17a};

R^{17a} is H, methyl, methoxy, -OH, F, Cl, CF₃, or OCF₃;

- R¹⁸, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and
- R¹⁹, at each occurrence, is independently selected from H, methyl, and ethyl.

26. (New) A compound according to Claim 14 of Formula (Ig):

or a pharmaceutically acceptable salt thereof wherein:

 \mathbb{R}^3 is \mathbb{R}^4 ,

 R^4 is C_1 - C_4 alkyl substituted with 0-1 R^{4a} , C_2 - C_4 alkenyl substituted with 0-1 R^{4a} , or C_2 - C_4 alkynyl substituted with 0-1 R^{4a} ;

R^{4a} is selected from

H, F, CF₃,

 C_3-C_6 carbocycle substituted with 0-3 R^{4b} , phenyl substituted with 0-3 R^{4b} , or

Serial No.: 09/505,788 Date: April 10, 2002

- 5 to 6 membered heterocycle containing 1 to 4
 heteroatoms selected from nitrogen, oxygen, and
 sulphur, wherein said 5 to 6 membered heterocycle is
 substituted with 0-3 R4b; wherein said 5 to 6 membered
 heterocycle is selected from pyridinyl, pyrimidinyl,
 triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl,
 piperazinyl, piperidinyl, pyrazolyl, imidazolyl,
 oxazolyl, isoxazolyl, and tetrazolyl;
- R^{4b}, at each occurrence, is independently selected from H, OH, Cl, F, NR¹⁵R¹⁶, CF₃, acetyl, SCH₃, S(=0)CH₃, S(=0)₂CH₃, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R^5 is C_1 - C_4 alkyl substituted with 0-1 R^{5b} ; C_2 - C_4 alkenyl substituted with 0-1 R^{5b} ; C_2 - C_4 alkynyl substituted with 0-1 R^{5b} ;

R^{5b} is selected from:

H, methyl, ethyl, propyl, butyl, CF_3 , OR^{14} , =0; C_3-C_6 carbocycle substituted with 0-2 R^{5c} ; phenyl substituted with 0-3 R^{5c} ; or

- 5 to 6 membered heterocycle containing 1 to 4
 heteroatoms selected from nitrogen, oxygen, and
 sulphur, wherein said 5 to 6 membered heterocycle is
 substituted with 0-3 R5c; wherein said 5 to 6 membered
 heterocycle is selected from pyridinyl, pyrimidinyl,
 triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl,
 piperazinyl, piperidinyl, pyrazolyl, imidazolyl,
 oxazolyl, isoxazolyl, and tetrazolyl;
- R^{5c}, at each occurrence, is independently selected from H, OH, Cl, F, NR¹⁵R¹⁶, CF₃, acetyl, SCH₃, S(=0)CH₃, S(=0)₂CH₃, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1-C_2 haloalkyl, and C_1-C_2 haloalkoxy;
- R^{10} is H, C(=0) R^{17} , C(=0) OR^{17} ;

Serial No.: 09/505,788 Date: April 10, 2002

C₁-C₄ alkyl optionally substituted with 0-1 R^{10a}; phenyl substituted with 0-4 R^{10b};

- C₃-C₆ carbocycle substituted with 0-3 R^{10b}; or
- 5 to 6 membered heterocycle containing 1 to 4
 heteroatoms selected from nitrogen, oxygen, and
 sulphur, wherein said 5 to 6 membered heterocycle is
 substituted with 0-3 R^{10b}; wherein said 5 to 6
 membered heterocycle is selected from pyridinyl,
 pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl,
 pyrrolyl, piperazinyl, piperidinyl, pyrazolyl,
 imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
- R^{10a} is selected from H, methyl, ethyl, propyl, butyl, OR^{14} , Cl, F, =0, $NR^{15}R^{16}$, CF_3 , or phenyl substituted with 0-4 R^{10b} ;
- R^{10b}, at each occurrence, is independently selected from H,

 OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy,

 propoxy, Cl, F, NR¹⁵R¹⁶, and CF₃;
- Z is C_1-C_3 alkyl substituted with 1-3 R^{12} ;
 - C2-C3 alkenyl substituted with 1-3 R12;
 - C_2-C_3 alkynyl substituted with 1-3 R¹²;
 - C₆-C₁₀ aryl substituted with 0-4 R^{12b};
 - C_3-C_6 carbocycle substituted with 0-3 R^{12b} ; or
 - 5 to 6 membered heterocycle containing 1 to 4
 heteroatoms selected from nitrogen, oxygen, and
 sulphur, wherein said 5 to 6 membered heterocycle is
 substituted with 0-3 R^{12b}; wherein said 5 to 6
 membered heterocycle is selected from pyridinyl,
 pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl,
 pyrrolyl, piperazinyl, piperidinyl, pyrazolyl,
 imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
- R^{12} , at each occurrence, is independently selected from C_6-C_{10} aryl substituted with 0-4 R^{12b} ; C_3-C_6 carbocycle substituted with 0-3 R^{12b} ; or

Serial No.: 09/505,788 Date: April 10, 2002

- 5 to 6 membered heterocycle containing 1 to 4
 heteroatoms selected from nitrogen, oxygen, and
 sulphur, wherein said 5 to 6 membered heterocycle is
 substituted with 0-3 R^{12b}; wherein said 5 to 6
 membered heterocycle is selected from pyridinyl,
 pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl,
 pyrrolyl, piperazinyl, piperidinyl, pyrazolyl,
 imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
- R^{12b}, at each occurrence, is independently selected from H, OH, Cl, F, NR¹⁵R¹⁶, CF₃, acetyl, SCH₃, S(=0)CH₃, S(=0)₂CH₃, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C_1 - C_2 haloalkyl, and C_1 - C_2 haloalkoxy;
- R¹³, at each occurrence, is independently selected from

 H. OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy,

 Cl. F. Br. CN, NR¹⁵R¹⁶, and CF₃;
- R¹⁴ is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;
- R¹⁵, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;
- R¹⁶, at each occurrence, is independently selected from

 H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl,

 methyl-C(=0) -, ethyl-C(=0) -,

 methyl-S(=0)₂-, and ethyl-S(=0)₂-;
- R¹⁷ is H, methyl, ethyl, propyl, butyl, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, phenyl substituted by 0-3 R^{17a}, or -CH₂-phenyl substituted by 0-3 R^{17a};
- R^{17a} is H, methyl, methoxy, -OH, F, Cl, CF₃, or OCF₃;
- R¹⁸, at each occurrence, is independently selected from



Serial No.: 09/505,788 Date: April 10, 2002

H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl; and

R¹⁹, at each occurrence, is independently selected from H, methyl, and ethyl;

provided, when R^{13} is H, then Z is C_2-C_3 alkenyl substituted with 1-3 R^{12} ; or C_2-C_3 alkynyl substituted with 1-3 R^{12} .

